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ABSTRACT 
The clonal distribution of BRAF
V600E
 in papillary thyroid carcinoma (PTC) has 
been recently debated. No information is currently available about precursor 
lesions of PTCs.  
My first aim was to establish whether the BRAFV600E mutation occurs as a 
subclonal event in PTCs. My second aim was to screen BRAF
 
 mutations in 
histologically benign tissue of cases with BRAF
V600E
 or BRAF
wt 
PTCs in order to 
identify putative precursor lesions of PTCs. Highly sensitive semi-quantitative 
methods were used: Allele Specific LNA quantitative PCR (ASLNAqPCR) and 
454 Next-Generation Sequencing (NGS).  
For the first aim 155 consecutive formalin-fixed and paraffin-embedded (FFPE) 
specimens of PTCs were analyzed. The percentage of mutated cells obtained was 
normalized to the estimated number of neoplastic cells. Three groups of tumors 
were identified: a first had a percentage of BRAF mutated neoplastic cells > 80%; 
a second group showed a number of BRAF mutated neoplastic cells < 30%; a third 
group had a distribution of BRAF
V600E 
between 30-80%. The large presence of 
BRAF
V600E
 mutated neoplastic cell sub-populations suggests that BRAF
V600E
 may 
be acquired early during tumorigenesis: therefore, BRAF
V600E
 can be 
heterogeneously distributed in PTC.  
For the second aim, two groups were studied: one consisted of 20 cases with 
BRAF
V600E
 mutated PTC, the other of 9 BRAF
wt
 PTCs. Seventy-five and 23 
histologically benign FFPE thyroid specimens were analyzed from the BRAF
V600E
 
mutated and BRAF
wt
 PTC groups, respectively. 
The screening of BRAF mutations identified BRAF
V600E in “atypical” cell foci 
from both groups of patients. “Unusual” BRAF substitutions were observed in 
histologically benign thyroid associated with BRAF
V600E 
PTCs. These mutations 
were very uncommon in the group with BRAF
wt
 PTCs and in BRAF
V600E 
PTCs. 
Therefore, lesions carrying BRAF
 mutations may represent “abortive” attempts at 
cancer development: only BRAF
V600E
 boosts neoplastic transformation to PTC. 
BRAF
V600E
 mutated “atypical foci” may represent precursor lesions of BRAFV600E 
mutated PTCs. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 The thyroid gland  
1.1.1 Embryology and anatomy  
The thyroid gland is a butterfly-shaped organ located on the anterior surface of the 
trachea at the base of the neck. It is the first endocrine gland to develop in the 
embryo: it begins to form from an outgrowth of the pharyngeal endoderm by the 
third week of gestation and ends by the eleventh. As the embryo grows it 
descends into the neck and for a short time the gland is connected to the 
developing tongue by a narrow tube, the thyroglossal duct. Thyroid remnants 
along this migration pathway, constitute in some individuals the pyramidal lobe 
whose incidence varies from 15% to 75%.  
The thyroid gland consists of two lobes and weighs about 15-25 g in adults. Each 
lobe is about 4 cm in length, 15-20 mm in width and 20-39 mm thickness: the 
lobes are connected together by a thin band of connective tissue called the 
isthmus, which is reported to be about 20 mm in length and width and about 2-6 
mm in thickness. The gland is covered by a thin fibrous capsule without true 
lobulations [1, 2].  
 
1.1.2 Physiology 
The functional unit of the thyroid gland is the follicle, a roughly spherical group 
of cells surrounding a central lumen filled with a protein-rich storage material 
called colloid. The follicles range in size 50-500 μm and are lined by cuboidal-to-
flat follicular epithelial cells. The follicular cells are orientated with their bases 
near the capillary blood supply and the apices abutting the colloid. Follicular cells 
are responsible for iodine uptake and thyroid hormone synthesis. 
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The thyroid also contains the parafollicular cells, which are neuroendocrine cells 
also called C-cells because they produce calcitonin, a hormone involved in 
calcium homeostasis (Fig. 1.1). 
The synthesis of thyroid hormones, L-triiodothyronine (T3) and L-thyroxine (T4), 
takes place in the follicular cells under the control of the hypothalamic-pituitary 
axis with negative feedback by the thyroid hormones. Thyrotropin releasing 
hormone (TRH), which is secreted from the hypothalamus, stimulates the release 
from the anterior pituitary gland of thyroid-stimulating hormone (TSH), which in 
turn stimulates the follicular cells to synthesize and secrete thyroid hormones. The 
hypothalamo-pituitary axis regulates the concentration of thyroid hormones in the 
circulation by a homeostatic feedback loop (Fig. 1.1). 
Different follicles may be in different states of activity: in less active follicles, 
follicular cells have a more cuboidal appearance, whereas the active follicles 
contain columnar cells. 
The process of thyroid hormone synthesis is complex: it demands the active 
uptake of iodide (I
-
) in exchange for Na
+
 by the follicular cells involving an 
ATPase-dependent transport mechanism. This enables the thyroid gland to 
concentrate iodide, which is oxidized to active iodine by hydrogen peroxide inside 
the follicular cell. This reaction is catalyzed by the heme-containing enzyme 
thyroid peroxidase (TPO). Then iodine is actively transported across the apical 
surface of the follicular cell by the same active process that occurs at the basal 
surface. 
At the apical-colloid interface, iodine is immediately incorporated into the 
tyrosine residues of a large glycoprotein synthesized in the follicular cells, 
thyroglobulin. Once iodinated, thyroglobulin is taken up into the colloid of the 
follicle where TPO catalyzes a coupling reaction between pairs of iodinated 
tyrosine molecules still incorporated in the protein. The coupling of two tyrosine 
residues each iodinated at two positions (di-iodotyrosine, DIT) produces tetra-
iodothyronine or thyroxine (T4) whereas the combination of DIT with mono-
iodotyrosine (MIT) produces tri-iodothyronine (T3). Thyroid hormones are stored 
in this state and are released only after stimulation by TSH: then, thyroglobulin 
droplets are captured by the follicular cells by a process of pinocytosis. Fusion of 
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the droplets with lysosomes results in hydrolysis of the thyroglobulin molecules 
and release of T4 and T3. Approximately 100 μg T4 and about 10 μg T3 are 
secreted from the gland each day, mostly in the form of T4 with about 10% as T3. 
Eighty percent of the T4 undergoes peripheral conversion in the liver and kidney 
to the ten times more active T3 or to reverse T3 (rT3) that has no significant 
biological activity. Since very small quantities of other iodinated molecules, such 
as MIT and DIT as well as thyroglobulin, are also measurable in the circulation, 
thyroglobulin measurement in the serum is used, for example, to detect 
endogenous thyroid secretion when patients are taking oral T4 replacement. 
Once released from thyroglobulin, over 99% circulating iodothyronines are 
rapidly bound to the plasma proteins: 70% is bound to thyroxine-binding globulin 
(TBG), 10-15% to transthyretin (previously called thyroxine-binding prealbumin) 
and 20-15% to albumin. These bound forms are in equilibrium with a tiny fraction 
in the free form in the circulation: only the free thyroid hormones can act on target 
cells. 
Thyroid hormones are lipid soluble and readily cross cell membranes: many of 
their actions are mediated by the binding to nuclear steroid hormone receptors that 
have higher affinity for T3. T3 receptors are members of a family of nuclear 
transcription factors that regulate gene expression in target cells and may remain 
bound to DNA also in the absence of hormone binding. When T3 binds to its 
receptor, it dimerizes with another T3 receptor to form a homodimer or with a 
different receptor, especially the retinoic acid receptor, to form a heterodimer. 
Dimerization allows gene expression regulation. In most tissues (excluding brain, 
spleen and testis) thyroid hormones stimulate the metabolic rate by increasing the 
number and size of mitochondria, stimulating the synthesis of enzymes in the 
respiratory chain and increasing membrane Na
+
-K
+
 ATPase concentration and 
membrane Na
+
 and K
+
 permeability. There is also evidence of rapid, non-genomic 
effects that thyroid hormones can have on membrane receptors such as 
stimulation of sugar transport, Ca
2+
ATPase activity and increased Na
+
 transport in 
muscle [2].  
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Figure 1.1. The thyroid gland and its control by the hypothalamic-pituitary axis [3].  
 
1.2 Human thyroid tumors 
1.2.1 Benign and malignant thyroid tumors 
The follicular cell-derived cancers represent the vast majority of thyroid tumors 
and are subdivided into well-differentiated papillary and follicular carcinomas 
(DTC), and less-differentiated thyroid cancers, including poorly differentiated 
carcinoma and anaplastic (undifferentiated) carcinoma (Fig. 1.2). Papillary thyroid 
carcinoma (PTC), the focus of this thesis, will be discussed in section 1.3. 
Follicular carcinoma (FTC) is a malignant epithelial tumor showing evidence of 
follicular cell differentiation and lacking the diagnostic nuclear features of 
papillary carcinoma (section 1.3.1). Follicular carcinomas are usually 
encapsulated solid tumors generally measuring more than 1 cm in diameter. 
Minimally invasive tumors are indistinguishable grossly from follicular adenomas 
except for thicker and more irregular capsule. Sometimes, widely invasive 
follicular carcinomas may lack any encapsulation. Neither architectural nor 
cytological atypical features, by themselves, are reliable criteria of malignancy 
since they may be found also in benign lesions, such as nodular (adenomatous) 
5 
 
goiter and adenoma. The diagnosis of malignancy depends on the demonstration 
of capsular or vascular invasion in histological preparations. Follicular carcinomas 
show variable morphology ranging from well formed colloid-containing follicles 
to solid or trabecular growth patterns with common coexistence of multiple 
architectural types. Follicular carcinomas are further subdivided into 
conventional, oncocytic and clear cell variants [4].  
Oncocytes, also called Hürthle cells, oxyphilic cells or Askanazy cells, are 
characterized by abundant granular cytoplasm due to aberrant accumulation of 
mitochondria that may be a compensatory mechanism to intrinsic defects in the 
energy production machinery of the cell. Thyroid tumors are designated as 
oncocytic if at least 75% of their cells are represented by oncocytes [5]. Clear 
cells contain glycogen, mucin, lipid or dilated mitochondria, therefore, this 
cellular change may be prominent in oncocytic tumors [4]. 
Poorly-differentiated thyroid carcinoma (PDC) is a malignant follicular- cell 
neoplasm that shows loss of structural and functional differentiation. It occupies 
an intermediate position between differentiated and undifferentiated carcinomas 
both morphologically and behaviorally. There are three different histological 
patterns: insular, trabecular and solid. These lesions show characteristic widely 
infiltrative growth, necrosis, vascular invasion and numerous mitotic figures. The 
diagnosis relies on the identification of the patterns in the majority of the tumor 
together with infiltrative growth, necrosis and vascular invasion [4]. 
Anaplastic thyroid carcinoma (ATC) is a widely invasive malignant tumor that is 
histologically composed wholly or partially of undifferentiated cells without 
structural follicular-cell differentiation. There are three main morphological 
patterns: squamoid, pleomorphic giant cell and spindle cell. These tumors have a 
very poor prognosis [4]. Many poorly differentiated carcinoma and anaplastic 
carcinoma arise through the process of stepwise dedifferentiation of papillary and 
follicular carcinomas, even though some can develop de novo [6]. 
Follicular adenoma (FA) is a benign, encapsulated epithelial tumor in which the 
cells show evidence of follicular differentiation. The architectural pattern and 
cytological features differ from the surrounding thyroid tissue. The most common 
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architectural features are follicular or trabecular. The tumor cells can be cuboidal, 
columnar or polygonal with round, dark nuclei or occasionally enlarged and 
hypercromatic. Occasionally, follicular adenomas can arise in a background of 
nodular hyperplasia from which is distinguishable by the encapsulation. By 
definition, capsular or vascular invasion are absent. Follicular adenomas are 
further subdivided into many histological variants such as the oncocytic type. 
Follicular adenoma may serve as a precursor for some follicular carcinomas [4].  
 
Figure 1.2. Scheme of step-wise dedifferentiation of follicular cell-derived thyroid cancer [6].  
Medullary thyroid carcinoma (MTC) is a malignant tumor originating from C-
cells. Approximately 25% of these neuroendocrine tumors are heritable: they are 
associated with multiple endocrine neoplasia (MEN) 2A and MEN2B or they 
arise as isolated heritable tumors in the familial medullary thyroid carcinomas 
(FMTC) syndrome.  
Tumors in sporadic and heritable form are generally indistinguishable; however, 
the heritable forms are typically associated with C-cell hyperplasia. The tumors in 
patients with sporadic disease may vary considerably in size but are usually 
unilateral while the MEN2-associated tumors are frequently bilateral and 
multicentric. The tumoral cells frequently have a diffuse or nesting growth pattern 
and are composed of polygonal, round or spindle cells, which are positive for 
calcitonin [4]. 
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1.2.2 Epidemiology 
Thyroid tumors account for 1% of all malignancies and represent the most 
common malignancy of endocrine organs. The vast majority of thyroid tumors 
arise from thyroid follicular epithelial cells, whereas 3% of cancers, referred to as 
medullary thyroid carcinomas, originate from C-cells. Papillary carcinoma 
accounts for about 80% of all thyroid cancers, followed by follicular carcinoma 
(~15%), poorly differentiated carcinoma (<1%) and anaplastic carcinoma (<2%) 
[4, 7]. 
Thyroid cancer typically occurs in thyroid nodules, which are common and can be 
detected by palpation and imaging in a large proportion of adults, particularly in 
women, of increased age. Palpable thyroid nodules show an estimated prevalence 
in population-based studies of 3-4%. The prevalence of non-palpable thyroid 
nodules incidentally detected by imaging approaches is 40%-50% after the age of 
60 years and is even higher on high-resolution ultrasound screening using 
sensitive high frequency (10-13 MHz) transducers [8-13].  
However, the vast majority of thyroid nodules is benign and can be managed 
conservatively: approximately 5-15% of nodules examined by ultrasound and 
fine-needle aspiration (FNA) cytology are malignant [14-18]. 
Although thyroid tumors are uncommon in childhood, PTCs represent the most 
common pediatric thyroid malignancy. Most PTCs in adults occur in patients 
between 20 and 50 year of age with a female to male ratio of 4-5:1 [19].  
In a 2004 survey, the average incidence in Europe has been reported to be 5.0 and 
12.9 cases per 100,000 residents per year among men and women, respectively 
[20]. In 2006, the average incidence of thyroid cancer in Italy has been estimated 
at 5.2 and 15.5 cases per 100,000 residents per year among men and women, 
respectively [21]. 
Incidence of thyroid cancer has increased rapidly in the past 15 years (Fig. 1.3). 
Many countries, including Europe, have had a doubling of incidence since the late 
1990s: the increase in incidence is almost exclusively attributable to papillary 
thyroid cancer [22]. 
The reasons why incidence of thyroid cancer is increasing are not completely 
understood, however, it has been proposed that it may be due to improved 
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diagnostic procedures that cause an increase in detection of small (<1 cm) and 
silent tumors incidentally noted on diagnostic imaging studies. Indeed, small 
papillary thyroid cancers account for most new diagnoses [23-25].  
Contrary to the hypothesis that improved diagnosis is the main cause of increased 
incidence of thyroid cancer, the prevalence of larger tumors is also increasing. 
Furthermore, higher rates of aggressive papillary thyroid cancers are being 
detected, including those with extrathyroidal extension, the tall-cell variant of 
papillary thyroid cancer, and distant metastases [26-28]. 
Moreover, thyroid cancer mortality has remained unchanged or even increased in 
recent years [20, 24, 29-31]. These data suggest that other factors might be 
affecting the biology and incidence of thyroid cancer [22]. 
 
Figure 1.3. Incidence of thyroid cancer in women since 1975 [22].  
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1.2.3 Risk factors 
Several risk factors have been linked to thyroid cancer including radiation 
exposure, reduced iodine intake, previous history of benign thyroid disease (such 
as nodules and autoimmune thyroid diseases), hormonal factors and family history 
(Table 1.4).  
Radiation exposure as a consequence of radioactive fallout from nuclear weapons 
or power plant accidents is associated with papillary carcinoma, as evidenced by 
the effects on health of the atomic bombs of Hiroshima and Nagasaki (1945), 
nuclear testing in the Marshall Islands (1954) and Nevada (1951-1962), and the 
nuclear accident in Chernobyl (1986) [4, 32]. After the Chernobyl disaster, the 
effects of radiation exposure were most pronounced in children: the possible 
reasons were a higher susceptibility of thyroid to radiation damage since thyroid 
growth occurs primarily in childhood and the fact that children drank more 
contaminated milk, increasing their exposure to radioactive iodine [33]. In the 
more recent nuclear accident in Fukushima (2011), dairy radiation levels were 
closely monitored after the disaster. According to WHO report, among infants 
from the most heavily affected areas, radiation would add one percentage point to 
their lifetime chances of developing cancer. However, women would have a 70% 
higher chance of developing thyroid cancer in their lifetimes, 1.25 out of every 
100 women [34]. 
Head or neck radiation treatments for benign condition in childhood is another 
risk factor for thyroid papillary carcinoma [35].  
Radiations seems to be closer linked to aberrant gene activation through 
chromosomal rearrangement rather than intragenic point mutation probably 
because radiations cause double strand breaks in DNA [4, 33, 36].  
Moreover, dietary iodine deficiency results in thyroid proliferation as a 
compensatory mechanism, known as goiter, and is linked to FTC. By contrast, 
PTC is the most frequent type of thyroid cancer in geographic regions of adequate 
or high iodine intake [4]. 
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In PTC is frequent the presence of lymphocytic infiltration, indicating that 
immunological factors might be involved in tumor progression [3].  
Epidemiological and morphological studies have suggested an increased risk of 
PTC in patients with Hashimoto’s thyroiditis (HT), autoimmune thyroid 
destruction. Coexistent HT is found in 11% to 36% of thyroids resected for PTC 
[37, 38]. Several studies support the concept of increased risk of PTC in patients 
with HT, particularly in women, however the relationship between HT and PTC 
remains to be determined [38-41]. A possible link between PTC and HT may be 
provided by solid cell nests (SCN) of the thyroid, composed of cells that may 
actually represent a pool of stem cells of thyroid and found in normal thyroid but 
observed at higher frequency in association with PTC and HT [42-44]. It has been 
suggested that at least a subset of PTC may be derived from these nests of 
multipotent cells, which may give rise to follicular cells and C cells, and 
morphologically mimicking papillary thyroid carcinoma [42]. This view is 
supported by molecular analysis that indicate the presence of the same BRAF
V600E 
mutation, the most frequent BRAF mutation in PTC (section 1.4.4), both in the 
SCN and in the adjacent PTC [45]. Cells derived from SCN may also represent 
incompletely developed thyroid tissue predisposed to autoimmune reaction 
resulting in HT. Therefore, both HT and PTC may be initiated by the same 
population of stem cell remnants and may thus be etiologically related [37]. 
As previously discussed, well-differentiated thyroid carcinomas occurs primarily 
in young and middle aged adults and are more frequent in females than in males. 
These sex and age distributions of incidence indicate that female hormones might 
have a role in thyroid carcinogenesis. Indeed, the estrogen receptor is expressed 
by follicular cells and estrogen promotes their proliferation [46, 47].  
There is also a genetic component in the risk of develop a thyroid follicular cell-
derived carcinoma: it increases 3.2- and 6.2-fold when a parent and a sibling, 
respectively, have had thyroid cancer [48]. About 5% of patients with DTC have a 
familial disease. Patients with familial non-medullary thyroid cancer have more 
aggressive tumors and frequently show the phenomenon of “anticipation”, earlier 
age at disease onset and increased severity in successive generations. 
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Some tumor syndromes have been linked to PTC. These inherited conditions, that 
are due to known germline mutations, include familial polyposis coli (FAP), 
Cowden disease, the syndromes referred to as familial site-specific papillary 
thyroid carcinoma, and perhaps Carney complex. However, the great majority of 
epithelial thyroid carcinomas seen in Cowden syndrome are follicular thyroid 
carcinomas: occasional PTCs observed typically belong to the follicular variant 
[4]. Other familial tumor syndromes that predispose to papillary carcinoma have 
been linked to several susceptibility gene loci, including syndromes associated 
with papillary renal cell carcinoma (1q21), clear-cell renal-cell carcinoma 
((3;8)(p14.2;q24.1)), and multinodular goiter (19p13.2) [3, 49, 50]. However, the 
far more common sporadic tumors do not harbor mutations in these loci [3]. 
 
Table 1.4. Etiological factors linked to the development of thyroid cancer [51].  
 
1.2.4 Staging and prognostic factors 
Since the extent of a cancer at time of diagnosis is essential to define treatment 
and its chance of success and also to allow comparison of groups of patients in 
clinical trials and who receive standard care, cancer staging systems are used. 
The tumor-node-metastasis (TNM) cancer staging system is endorsed by the 
American Joint Committee on Cancer (AJCC) and the Union for International 
Cancer Control (UICC) and updated periodically. This system codes the extent of 
the primary tumor (T), regional lymph nodes (N), and distant metastases (M) and 
provides a ‘‘stage grouping’’ based on T, N, and M [52]. 
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The seventh edition of the AJCC Cancer Staging Manual is most widely used 
(Table 1.5), although other classification systems exist and, for example, MACIS 
(metastasis, age, completeness of resection, invasiveness, and size) has some 
support as an alternative system [53, 54]. 
In TNM system, stage I disease includes patients less than 45 years of age with 
any T, any N, but without distant metastases (M0) and also most micropapillary 
cancers (TNM class T1a; Table 1.5). Patients older than 45 years of age are 
classified as stages I to IV [4]. 
 
Table 1.5. TNM classification system for differentiated thyroid carcinoma [22].  
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1.2.5 Multi-step carcinogenesis of thyroid neoplasms 
According to the proposed model of thyroid carcinogenesis, risk factors, including 
exposure to radiation, induce genomic instability through direct and indirect 
mechanisms, resulting in early genetic alterations that involve the mitogen 
activated protein kinase (MAPK) signaling pathway. Oncogenic activation of 
MAPK signaling further increases genomic instability of thyroid carcinoma cells, 
possibly leading to later genetic alterations during cancer progression that involve 
other signaling pathways, cell-cycle regulators and adhesion molecules. This 
important role of genomic instability in thyroid cancer is highlighted in Figure 1.6 
[3]. 
Follicular adenomas and carcinomas are frequently aneuploid with a high 
prevalence of loss of heterozygosity (LOH) involving multiple chromosomal 
regions. This chromosome instability is in contrast to the diploid or near-diploid 
content of most papillary carcinomas indicating discrete molecular pathways for 
these different types of thyroid tumors [55-57].  
Transfection of mutant BRAF
V600E
 induces genomic instability in a rat thyroid cell 
line, manifesting as loss of chromosomal material, mitotic bridge formation and 
misaligned chromosomes [58-60]. 
 
 
Figure 1.6. Genomic instability role in thyroid cancer.  
Thyroid cancer initiation and progression occurs through gradual accumulation of 
various genetic and epigenetic alterations. In Figure 1.7 is depicted thyroid multi-
step tumorigenesis model. 
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Figure 1.7. Thyroid multi-step tumorigenesis model [3].  
Hyper-functioning follicular thyroid adenoma, tumors that are almost always 
benign lesions without a propensity for progression, follicular thyroid carcinoma 
and papillary thyroid carcinoma follow three distinct multi-step tumorigenesis 
pathways.  
Gain-of-function mutations in the genes of TSH receptor (TSHR), a seven-
transmembrane-domain G-protein-coupled receptor, and that encoding guanine 
nucleotide-binding α-subunit 1 (GNAS1), activate cAMP, thereby regulating 
thyroid hormone synthesis and the growth of follicular cells [61]. 
TSHR and GNAS1mutations occur in hyper-functioning thyroid adenomas but are 
rare in thyroid malignancies indicating that constitutive activation of the cAMP 
cascade alone is insufficient for the malignant transformation of thyroid follicular 
cells [3, 62]. 
In thyroid cancer critical genes are frequently mutated via two distinct molecular 
mechanisms: point mutation or chromosomal rearrangement. The main signaling 
pathways involved in thyroid carcinogenesis are MAPK and PI3K-AKT pathways 
(Fig. 1.8).  
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Figure 1.8. MAPK and PI3K-AKT signaling pathways [6].  
 
Mutations and rearrangements described in thyroid cancer and their average 
prevalence are summarized in Table 1.9.  
 
 
Table 1.9. Molecular alterations and their average prevalence in thyroid cancer [17].  
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MAPK activation is crucial for tumor initiation: indeed, among known mutated 
genes in thyroid cancer can be found that encoding cell-membrane receptor 
tyrosine kinases RET and NTRK1 and intracellular signal transducers BRAF and 
RAS. Papillary carcinomas may carry point mutations of the BRAF and RAS 
genes and RET/PTC and TRK rearrangements. These activating mutations are 
mutually exclusive and can be found in about 70% of papillary thyroid 
carcinomas [17, 63, 64].  
Gain of function mutations of RET (REarranged during Transfection), located on 
chromosome 10q11.2, are involved in sporadic (~40%) and familial C-cell-
derived medullary thyroid carcinoma (~80%), including multiple endocrine 
neoplasia 2A (MEN2A), MEN2B and familial medullary thyroid carcinoma [3, 
65]. RET can be also altered by chromosomal rearrangements forming chimeric 
oncogenes, designated RET/PTC, that are involved in the development of 
papillary carcinoma. Somatic chromosomal rearrangement leads to fusion of the 
3ʹ-terminal sequence of RET, which encodes the tyrosine kinase domain, with the 
5ʹ-terminal sequences of heterologous genes. Wild-type RET is not normally 
expressed in follicular cells, whereas RET/PTC chimeric oncoproteins lack a 
signal peptide and transmembrane domain and are, therefore, expressed in the 
cytoplasm of follicular cells, under the control of the acquired promoters. Ligand-
independent tyrosine phosphorylation is induced by constitutive dimerization of 
the fusion proteins and causes activation of signaling pathway [3, 66]. More than 
17 RET/PTC rearrangements have been described [65]. In sporadic PTC the most 
common form is RET fusion with CCDC6 (coiled-coil domain containing 6), also 
known as RET/PTC1, followed by RET fusion with NCO4 (Nuclear coactivator 
4), also known as RET/PTC3. These rearrangements represent more than 90% 
with RET/PTC1 being detected in about two thirds and RET/PTC3 in about one 
third of all positive cases [66]. RET rearrangements show high incidence (~80%) 
in PTC from patients exposed to radiations [67]. In PTC, they can be a subclonal 
event and can be also found in histologically benign thyroid nodules or in 
Hashimoto’s thyroiditis [68-72]. 
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The RAS gene family is composed by KRAS, HRAS and NRAS: these genes codify 
for G- proteins and their activation has been reported in all non-medullary thyroid 
tumors. Mutations of KRAS and HRAS have also been reported in sporadic 
medullary thyroid carcinomas. RAS mutations can frequently affect codon 61 of 
HRAS and NRAS in thyroid tumors and can be found in follicular adenomas 
(~35%), follicular carcinomas (~40%) and in the follicular variant of papillary 
carcinomas (~35%) [3, 6, 73]. Since RAS mutations can be also found in benign 
hyperplastic nodules, they are not specific for malignancy [74]. 
In follicular thyroid cancer, in addition to RAS mutations, another common event 
is PAX8/PPARγ rearrangement [75]. The peroxisome proliferator-activated 
receptor-γ (PPARγ), encoded by PPARG (located on chromosome 3p25), is a 
member of the steroid nuclear hormone receptor superfamily and is related to 
differentiating effects on adipocytes and insulin-mediated metabolic functions. 
Paired-box gene 8 (PAX8) encodes a transcription factor involved in the 
maintenance of the differentiated phenotype of thyroid follicular cells. PAX8-
PPARG rearrangements were first identified in follicular thyroid neoplasms with 
the cytogenetically detectable translocation t(2;3)(q13;p25) that generates a 
chimeric gene encoding the DNA-binding domain of the thyroid-specific 
transcription factor PAX8 and domains A-F of PPARγ. The mechanisms of 
transforming activity remain to be fully understood [3]. PAX8/PPARγ occurs in 
follicular thyroid carcinoma with a frequency of ~30%, and is also found in a 
small proportion of follicular adenomas (<13%) and of the follicular variant of 
papillary carcinomas (~10%) [73]. The activating mutations described in follicular 
carcinomas are also mutually exclusive and identified in approximately 80% of 
these cancers [17].  
BRAF and RAS mutations are frequently found in both well-differentiated thyroid 
cancer and in poorly differentiated and anaplastic carcinomas, thus, probably 
representing an early event in thyroid cancer progression. However, thyroid 
cancer progression and dedifferentiation involve a number of additional mutations 
that affect other cell signaling pathways. Late events, not found in well-
differentiated cancers but frequently found in anaplastic and poorly differentiated 
18 
 
carcinomas, include point mutations of the TP53 and CTNNB1 genes, encoding 
p53 and β-catenin respectively, as well as mutation in genes that encode effectors 
of the PI3K-AKT signaling pathway [6, 76-78]. 
 
1.3 Papillary thyroid carcinoma (PTC) 
1.3.1 Histopathology 
Papillary carcinoma (PTC) is a malignant epithelial tumor showing evidence of 
follicular cell differentiation, characterized by papillary growth and diagnosed on 
the basis of distinctive nuclear features. Papillary architecture is typically complex 
with branching in which the surfaces of the papillary cores are covered by 
neoplastic cells. In tumor lacking complex papillary structures, the diagnosis 
relies on the nuclear features. These diagnostic features include nuclear 
enlargement and irregularity, overlapping, clearing (ground glass or Orphan 
Annie appearance), grooves, and pseudoinclusions. Indeed, these nuclei are larger 
and more oval than normal follicular nuclei and contain hypodense chromatin. 
Moreover, they show the presence of grooves, often overlap one another and 
intranuclear inclusions of cytoplasm can be observed [4].  
These nuclear features allow PTC to be distinguished from nodular goiter, 
follicular adenomas and diffuse hyperplasia sometimes showing papillary 
structures. Indeed, some of the histologic changes that can be observed in thyroid 
hyperplasia (HYP), an enlargement of the thyroid gland that does not result from 
inflammation or neoplasia and whose most common manifestation is the sporadic 
goiter, can sometimes lead to an incorrect diagnosis of malignancy [79]. 
In PTC a pure papillary growth is uncommon: this architectural pattern often 
coexist with other patterns such as varying sized follicles, solid and trabecular. 
Squamous metaplasia is common and, in cystic tumors, may be extensively 
present at the cyst lining. Intratumoral fibrosis, peritumoral lymphocytic infiltrates 
and psammoma bodies are also common features of these tumors [4, 80]. 
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Psammoma bodies (PBs) are 50-70 µm in size rounded and concentrically 
lamellated calcifications observed in PTC and rarely in non-neoplastic lesions, 
including Hashimoto’s thyroiditis, multinodular goiter or benign hyperplastic 
thyroid nodules [81-84]. They are present in paraffin sections of approximately 
40-50% PTC cases. Psammoma bodies are usually present within the cores of 
papillae, in the tumor stroma, or in lymphatic vessels, but not within the colloid of 
neoplastic follicles [80]. As early as 1959, Klinck and Winship considered PBs in 
PTC as the remnants of dead papillae [85]. Residual neoplastic cells are 
sometimes observed intimately associated with PBs in PTC [86]. PBs are 
considered the result of focal areas of infarction of the tips of papillae, attracting 
calcium that is deposited on the dying cells [87, 88]. According to another theory, 
an intracellular accumulation of calcium by tumor cells leads to their death and 
release of the calcium. Progressive infarction of the papilla and following calcium 
deposition lead to lamellation. [86]. PBs may represent, also in benign lesions, the 
remnants of neoplastic papillae. The deposition of collagen and concentric 
calcification in the central vascular core may lead to compromise in nutrient 
supply to the tumor cells resulting in their degeneration or necrosis and 
disappearance. This may be one of the reasons behind finding of PBs in 
Hashimoto’s thyroiditis and colloid goiters, in areas away from the PTC tumor 
mass. Moreover, the degeneration and necrosis of tumor cells following the 
formation of PBs may also explain partly the indolent course and excellent 
prognosis associated with PTC. Therefore, PBs may also act as a barrier against 
the spread of tumor cells [86]. However, in a recent study a significant correlation 
between the presence of PBs and tumor multifocality, extrathyroidal extension, 
and lymph node metastasis in PTCs was observed, suggesting that the presence of 
PBs may predict aggressive tumor behaviors in PTC patients [89]. 
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1.3.2 Histopathological variants and associated molecular 
alterations 
PTC can be further classified into numerous histologically distinct variants, 
including the most common classical PTC, follicular-variant PTC, and tall-cell 
PTC, and uncommon such as oncocytic, solid and cribriform subtypes, each with 
distinct growth patterns and behaviors [90]. 
Classical PTCs (PTC Cl) are characterized by a complex branching architecture in 
which the surfaces of the papillary cores are covered by neoplastic cells [4].  
Follicular variant PTCs (PTC FV) are composed almost exclusively of follicles 
having the characteristic nuclear features of PTC and may be encapsulated 
(approximately one third of the tumors) or non-encapsulated. The follicular 
variant is one of the most common and most diagnostically challenging: inter-
observation variation in the diagnosis of these tumors, particularly the 
encapsulated type, is high since the nuclear features may be focal or poorly 
developed. Lymph node metastases and rarely hematogenous metastasis can occur 
despite complete encapsulation, however prognosis is similar to conventional PTC 
[4, 19, 91]. 
The tall cell variant of PTC (PTC TC) is a rare variant defined by cells that are at 
least three times as high as they are wide, an eosinophilic cytoplasm, and the 
nuclear features of PTC [4, 92]. 
Histopathological findings show the tumors to be a combination of papillary, 
trabecular or cord-like patterns while follicular structures are rare. This variant has 
been poorly defined because the height of the neoplastic cell is variable, 
depending also upon the plane of section, and because a significant proportion of 
tall cells is present in different types of papillary carcinoma leading to 
misdiagnosing. A diagnosis of the tall cell variant of PTC is made when 50% of 
cells are tall cells [92].  
In this variant necrosis, mitosis and extrathyroidal extension are common. Tall 
cell variant occur in older patients, often males, and shows a more aggressive 
clinical behavior than conventional PTCs [4]. 
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As previously discussed in section 1.2.5, PTCs show typically mutually exclusive 
mutations occurring in approximately 70% of cases: these molecular alterations 
are associated with particular clinical, histopathological and biological tumor 
characteristics described in Figure 1.10 [6]. Indeed, BRAF
V600E 
mutation is 
typically found in papillary carcinomas with classic papillary and tall cell 
histology cell and is rare in the follicular variant of papillary carcinoma [93, 94]. 
By contrast, BRAF
K601E
 mutation is typically found in the follicular variant of 
papillary carcinoma. BRAF mutations will be further discussed in sections 1.4.4-
1.4.6 [95, 96]. 
Moreover, virtually all PTCs that harbor a RAS mutation grow forming neoplastic 
follicles and no papillary structures and are, therefore, diagnosed as follicular 
variant of papillary carcinoma [93, 97]. Moreover, BRAF point mutation is most 
common in sporadic tumors, whereas AKAP9-BRAF rearrangement is more 
common in papillary carcinomas associated with radiation exposure. AKAP9-
BRAF rearrangement results in a fusion protein containing the protein kinase 
domain and lacking the autoinhibitory N-terminal portion of BRAF. This mutant 
protein shows elevated kinase activity and transforms NIH3T3 cells. [36].  
 
Figure 1.10. Average prevalence of molecular alterations in PTC and their association with clinical and 
histopathological features [6].  
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1.3.3 Papillary thyroid microcarcinoma (mPTC) 
The term microcarcinoma includes different definitions used in the past, such as 
small carcinoma, minimal carcinoma, occult carcinoma, non-palpable carcinoma 
and incidentaloma. Since almost all the tumors are of papillary histotype, the 
preferred definition is now micro-Papillary Thyroid Carcinoma (mPTC). Papillary 
thyroid microcarcinoma is defined as papillary carcinoma of 1 cm or less in size 
commonly incidentally found in thyroids removed for other reasons, including 
benign clinical nodules or diffuse processes such as thyroiditis, and in autopsy 
series [4].  
Indeed, mPTCs occur in up to 30% of autopsies and in up to 24% of surgical 
thyroidectomies performed for disorders unrelated to PTC [19, 98]. These tumors 
are commonly located near the thyroid capsule, are often non-encaspsulated and 
sclerosing. In children mPTC can show a more aggressive behavior and rarely in 
adults may present with cervical nodal metastasis [4]. 
Indeed, papillary microcarcinoma is an extremely indolent tumor, however, up to 
11% of thyroid microcarcinomas are the primary lesion to a lymph node 
metastasis presenting clinically as a neck mass and can exhibit local recurrences. 
In this situation, the tumor should be treated as a clinical cancer. Multifocality in 
mPTC is reported in 20% to 46% of cases and up to 40% of these patients can 
present with lymph node metastases [99]. Clinicopathological features, such as 
age more than 45 years, tumor size greater than 5 mm, male sex, multifocality, 
lymph nodes metastasis, and extrathyroidal extension have been reported to 
predict poor prognosis [100, 101]. The disease-specific mortality rate from mPTC 
is up to 2% in some series [102, 103].  
Familial cases of papillary thyroid microcarcinoma with unfavorable behavior 
have also been reported [104]. Among risk factors, irradiation to the thyroid is 
considered predisposing for mPTC, however, this tumor does not show a strong 
sex predilection as compared with other thyroid diseases, which are more 
common in women [99]. 
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Molecular analysis of mPTC showed the presence of RET/PTC rearrangements 
with a frequency of 42.3% and 52.0% in two different series and BRAF mutations 
in 17.6%-70% [105-111].  
Therefore, both RET/PTC rearrangements and BRAF mutations may represent 
early genetic lesions in papillary thyroid cancer [112]. A high prevalence of this 
mutation was observed in certain histologic subtypes (classic, tall cell, 
subcapsular and occult sclerosing variants) in contrast to the follicular variant of 
papillary thyroid microcarcinoma [106, 108, 111]. 
 
1.4 Oncogene BRAF and its role in papillary thyroid 
carcinoma  
1.4.1 Gene and protein function 
The BRAF gene (v-raf murine sarcoma viral oncogene homolog B) is located on 
the long arm of chromosome 7 at position 34 (7q34) and covers about 190 kb. It 
contains 18 coding exons and 5 splice variants have been identified: the full-
length transcript is made up of 2,480 bp and encodes a full-length protein of 766 
amino acids (94 kDa) [113-115]. 
BRAF is a serine-threonine kinase belonging to the family of RAF proteins. There 
are three isoforms of RAF proteins originating from 3 independent genes in 
mammals: ARAF, BRAF, and CRAF (also called RAF-1) [116]. These serine-
threonine protein kinases are intracellular effectors of the conserved 
RAS/RAF/MEK/MAPK signal transduction pathway (Fig. 1.11). This pathway is 
activated by growth factors, hormones, and cytokines and propagate signals from 
cell membrane receptor tyrosine kinases (RTKs) to the nucleus where 
transcription of genes involved in cell differentiation, proliferation, and survival is 
regulated [117].  
The ligand-mediated activation of receptor tyrosine kinases triggers the release of 
guanosine diphosphate (GDP) and guanosine triphosphate (GTP) loading of the 
RAS GTPase: this active state of RAS G-proteins can cause activation of the 
MAPK and other signaling pathways, such as PI3K-AKT. Normally, the activated 
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members of the RAS family of proteins, including KRAS, HRAS, and NRAS, 
becomes quickly inactive due to their intrinsic guanosine triphosphatase (GTPase) 
activity and the action of cytoplasmic GTPase-activating proteins. RAS proteins 
are attached to the inner surface of the plasma membrane and their activation 
triggers recruiting of RAF kinases to the cell membrane for activation and result 
in phosphorylation and activation of downstream targets along the MAPK 
cascade. RAF triggers phosphorylation and thus activation of the mitogen-
activated protein kinase (MAPK)-extracellular signal-regulated kinases 1 and 2 
(MEK1 and MEK2), which in turn phosphorylate extracellular signal-regulated 
kinases 1 and 2 (ERK1 and ERK2) on threonine and tyrosine residues. ERK1 and 
ERK2 regulate cellular functions through phosphorylation of both cytosolic 
proteins and nuclear substrates such as transcription factors [118].  
 
 
Figure 1.11. The mitogen-activated protein kinase (MAPK) signaling pathway [119].  
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1.4.2 RAF protein structures 
All RAF proteins share three conserved regions (CR) with distinct functions: the 
regulatory domains CR1 and CR2 at the N terminus and the kinase domain CR3 at 
the C terminus (Fig. 1.12) [120].  
CR1 encompasses a RAS binding domain (RBD) necessary for the interaction 
with GTP-bound activated RAS and with membrane phospholipids. CR1 contains 
also a secondary RAS-binding site, a cysteine rich domain (CRD), which is also 
required for the interaction of CR1 with the kinase domain for RAF autoinhibition 
[121, 122].  
CR2 contains inhibitory phosphorylation sites involved in the negative regulation 
of RAS binding and RAF activation: their dephosphorylation is prerequisite for 
RAS binding and RAF activation [123].  
CR3 includes the kinase domain with the activation segment, a region of 10-30 
amino acids bounded by almost invariant DFG and APE motifs, in which the 
phosphorylation sites, threonine and serine residues necessary for kinase 
activation, are located.  
There is also a negatively charged (N) region upstream of the CR3 whose 
phosphorylation is necessary for RAF activation and a glycine-rich loop (G-loop) 
which clamps ATP into the catalytic cleft forming a loop that anchors the - and 
-phosphates of ATP [124].  
Differences in the N region of ARAF, BRAF, and CRAF have an important role 
for the differential regulation of these isoforms: in CRAF, the phosphorylation of 
S338 and Y341 is necessary for activation by RAS (homologous to S299 and 
T302 respectively in ARAF). Unlike ARAF and CRAF, BRAF N-region carries a 
constitutive negative charge that primes it for activation. Indeed, in BRAF the 
constitutive phosphorylation of the serine 446 (homologous to CRAF S338) 
residue and the replacement of Y340 and Y341 by aspartic acids (D448 and 
D449) imply that dephosphorylation of negative regulatory sites and RAS binding 
are probably the only requirements for BRAF activation [118, 125-129].  
In the inactive conformation RAF is believed to form a closed structure, with the 
regulatory domain (in particular the cysteine rich domain) interacting with the 
kinase domain. During activation, this closed conformation is destabilized 
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allowing for RAS binding and membrane recruitment, thus obtaining a stabilized 
‘open’ active conformation [130, 131].  
The recruitment to the plasma membrane is necessary for the activation of all 
RAF isoforms because the activation segment phosphorylation and, in the case of 
ARAF and CRAF, also N-region phosphorylation occur at the plasma membrane 
[130]. 
 
 
 
Figure 1.12. Common schematic structure of the RAF proteins [129]. CR 1-3, conserved regions; RBD, 
RAS-binding domain; CRD, cysteine-rich domain.   
In BRAF the phosphorylation of threonine 599 and serine 602 (homologous to 
T491 and S494 in CRAF) in the activation loop of CR3 is essential for activation 
by RAS: T599 is the major activation segment phosphorylation site, whereas S602 
is a relatively a minor one [125, 126, 132].  
The crystal structure of BRAF has revealed intramolecular hydrophobic 
interactions between the glycine-rich loop (shown in green in Fig. 1.13) and the 
activation segment (shown in magenta in Fig.1.13) that establish a BRAF inactive 
conformation displacing the DFG motif in activation segment, which includes a 
catalytic aspartate residue, to a position that is incompatible with catalysis. 
Phosphorylations within the activation segment or amino acid substitutions in 
both regions of the kinase can break these intramolecular interactions and activate 
BRAF [129, 130].  
T599 phosphorylation is essential for BRAF activation through the release of the 
activation segment and reorientation of critical residues into the correct position 
for catalysis: this residue is positioned at the interface of the glycine-rich loop and 
activation segment interaction domain and probably disrupts the interaction 
allowing the DFG motif to adopt the active conformation.  
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Moreover, D448 in the N region (shown in rust in Fig. 1.13) contacts R506 of the 
αC-helix (the interaction is shown by the red dashed line in Fig. 1.13) stabilizing 
the active conformation: this may be the reason why this aspartate is important for 
the basal and RAS-stimulated kinase activity of BRAF [130].  
 
 
Figure 1.13. BRAF kinase domain structure. A portion of the activation segment is disordered and is 
indicated by the dashed magenta line. T599 phosphorylation site is colored yellow. In the structure of the 
BRAF kinase domain (residues 448-726), BAY43-9006, the inhibitor that BRAF was crystallized with, has 
been omitted [118].  
Among the three RAF isoforms, BRAF is the most potent activator of the MAPK 
pathway and is by far the most frequently mutated RAF protein in human cancer: 
the explanation lies in these fundamental regulatory differences [126, 133]. 
 
1.4.3 BRAF mutation prevalence 
BRAF-activating mutations were discovered in 2002 and enlarged the number of 
known genetic alterations that activate the MAP kinase pathway, further 
confirming the importance of this pathway in human cancer. BRAF is commonly 
activated by somatic point mutation in a range of human cancers. BRAF somatic 
missense mutations can be found malignant melanoma (27%-70%), colorectal 
cancer (5%-22%), serous ovarian cancer (~30%) and at lower frequency in a 
variety of other human cancers (1%-3%) [118, 134].  
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BRAF mutations in thyroid cancer show a prevalence second only to that in 
melanoma. Point mutations of the BRAF gene are the most common genetic 
alteration in thyroid papillary carcinomas: they can be found in 40%-45% of these 
tumors [135, 136].  
Activating point mutations of the BRAF gene are clustered in the kinase domain in 
exons 11 (G-loop) and 15 (activation segment) of the gene: mutations in exon 11 
of the BRAF gene were not found in thyroid cancer [63, 134-136].  
Most of them are point mutations in exon 15 involving nucleotide 1799 that result 
in a valine to glutamate substitution at residue 600 (V600E): BRAF
V600E
 accounts 
for about 95% of BRAF mutation in thyroid papillary carcinomas. The association 
of PTCs with the BRAF
V600E
 mutation was demonstrated in numerous studies with 
patients from different geographical and ethnic backgrounds supporting the 
fundamental role of this mutation in the pathogenesis of thyroid papillary 
carcinoma [94, 119, 137].  
In papillary thyroid carcinoma, BRAF
V600E
 is typically found in tumors with 
classic papillary (60%) and tall-cell histology (80%) and is rare in the follicular 
variant (10%) (Fig. 1.14) [93, 94].  
 
 
Figure 1.14. Prevalence of BRAF mutations in different histologic variants of thyroid papillary 
carcinoma (Hematoxylin-Eosin, original magnification ×100) [119].  
Therefore, BRAF
V600E
 mutation in papillary thyroid carcinoma shows a subtype-
related prevalence that may explain the tendency of tall-cell and classic PTC 
subtypes to be more aggressive than follicular-variant PTC: this is consistent with 
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the idea that BRAF
V600E
 mutation has a causal role in thyroid cancer’s aggressivity 
[94, 138].  
Since the other subtypes of PTC are uncommon, the prevalence of BRAF
V600E
 
mutation in these tumors has rarely been reported: in a study by Trovisco et al. 
BRAF
V600E
 mutation was found in six out of 15 (40%) oncocytic-variant PTCs and 
six out of eight (75%) Warthin-like PTCs, but not in diffuse sclerosing PTCs, 
columnar cell variant PTC, hyalinizing trabecular thyroid tumors, or in 
mucoepidermoid thyroid tumors [96].  
BRAF
V600E
 mutation has also been found in poorly differentiated and anaplastic 
thyroid carcinomas (24%), especially in those tumors with the co-existence of 
areas of well differentiated papillary carcinoma. In these tumors both areas 
harbored BRAF
V600E
 mutation suggesting that they were likely derived from BRAF 
mutation-positive PTCs and that BRAF
V600E
 is an early event in the tumorigenesis. 
BRAF
V600E 
has not been identified either in follicular thyroid carcinomas, although 
in these tumors BRAF up-regulation may happen through increased gene copy 
number, or medullary thyroid carcinomas or benign thyroid neoplasms (adenoma 
or hyperplasia). Therefore, this mutation can be considered a quite specific marker 
of papillary thyroid carcinoma [94, 139, 140].  
Other BRAF mutations have been found in 1% to 2% of papillary thyroid 
carcinomas, including other point mutations, small in-frame insertions or 
deletions and rearrangements [119]. 
Among point mutations, BRAF
K601E
 was detected in two follicular adenomas (one 
from a study in post-Chernobyl tumors), in the follicular variant of PTC (7-10% 
of PTC FV) and in one sample of a case of classical follicular thyroid carcinoma 
(the first case found of a classical FTC carrying a BRAF mutation) whereas, as 
previously discussed, BRAF
V600E
 mutation appears to be prevalent in PTC with a 
predominantly papillary architecture: these data support the hypothesis that the 
follicular variant of PTC shows genetic differences from conventional PTC [64, 
96, 141-144]. 
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1.4.4 BRAF
V600E
 mutation 
BRAF
V600E
 mutation is a thymidine to adenosine transversion at nucleotide 1799 
converting valine to glutamate at hot spot codon 600 (V600E) and resulting in 
constitutive activation of BRAF and the MAPK signaling pathway [130, 134].  
This mutation had been previously called T1796A, based on the NCBI GenBank 
nucleotide sequence NM_004333, which missed a codon in exon 1 of the BRAF 
gene. The assessment of the NCBI GenBank nucleotide sequence NT_007914 
version correctness caused a change in nucleotide numbering after nucleotide 94 
(starting from ATG codon), therefore, this BRAF mutation is now designated 
T1799A [145].  
BRAF
V600E
 activates BRAF kinase by mimicking phosphorylation of the 
activation segment through the insertion of a negatively charged residue beside 
the conserved regulatory phosphorylation sites T599 and S602: this substitution 
disrupts the association of the activation segment with the ATP-binding domain 
converting BRAF to a catalytically active conformation. 
Since the substitution at the position of a regulatory phosphorylation site from a 
threonine or serine residue to an acidic amino acid cannot be generated by a single 
base change, such mutations are probably rare in human disease, therefore amino 
acids other than threonine and serine can be more frequently mutated to acidic 
residues to mimic phosphorylation and activate kinases. Thus, it’s likely that a 
glutamate mutation at residue 600 occurs at high frequency because it only 
requires a single base substitution. This phospho-mimetic substitution is one of 
the most active mutants harboring an in vitro kinase activity about 500 fold 
greater than that of wild-type BRAF and enhancing ERK activation by about 4-
fold in COS cells [94, 130, 134]. 
The transforming and oncogenic potential of the BRAF
V600E
 mutation has been 
widely shown: in NIH3T3 mouse embryonic fibroblast cells and murine 
melanocytes, this mutation stimulates constitutive ERK signaling, induces 
proliferation and transformation, and allows these cells to form tumors when 
assayed for tumorigenicity in nude mice [118, 130, 131, 134, 146].  
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BRAF
V600E
 mutation represents a somatic genetic alteration in sporadic thyroid 
cancers and is not a germline mutation in familial non-medullary thyroid cancer 
[136, 147, 148].  
Germline variations at the valine 600 residue were not found in a large case study 
of malignant melanomas too [149].  
 
1.4.5 Other BRAF
 
mutations of V600 residue 
In addition to BRAF
V600E
 mutation, numerous other BRAF substitutions have been 
rarely described in papillary thyroid carcinoma and other cancers and some of 
them have also been tested with respect to the activation or impairment of the 
kinase activity of BRAF.  
In a functional study performed by Wan and colleagues, BRAF mutants were 
divided in three groups according to their in vitro basal BRAF kinase activity: in 
the high activity group were collected mutants approximately 130 (BRAF
E586K
) to 
700 (BRAF
V600D
) fold more active than basal BRAF
wt
, in the intermediate activity 
group those 1.3 (BRAF
G469E
) to 64 (BRAF
L597V
) fold higher than BRAF
wt
 and in 
the impaired activity group those mutants whose basal kinase activities were 
reduced. 
V600 residue can be mutated to other amino acids whose activities are similar to 
that of BRAF
V600E
: these mutations can be found at a very low frequency in cancer 
(0.1% to 2%) probably because they are the result of tandem nucleotide changes, 
which are very rare. V600K is an example of such mutations [118, 130].  
In a study by Brzeziańska and colleagues, mutational screening of exon 15 of 
BRAF gene by direct sequencing in papillary thyroid carcinoma in the Polish 
population revealed the presence of two uncommon heterozygous missense 
mutations that had not been previously described in thyroid tumors. They 
observed in two cases the overlapping mutations V600K/V600E where the 
presence of V600E mutation was confirmed by real-time allele specific and in a 
different case a V600M mutation. V600K mutation is the result of a 2-bp change 
(GT1798-99AA), whereas V600M is a single nucleotide substitution in the first 
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nucleotide position (G1798A) in codon 600 of BRAF gene [150]. V600K mutation 
had not been previously described in thyroid tumors but it had been reported in 
human malignant melanomas as the second, regarding the frequency, after V600E 
mutation [149]. Authors suggested that G1798A and T1799A found by direct 
sequencing were most likely to occur on the same chromosome: thus, these in cis 
base substitution resulted in a V600K mutation in one allele [150]. This mutation 
seems to be characteristic for invasive and metastatic melanoma [151-153]. 
V600K is an activating mutation that causes a substitution of valine for a 
positively charged lysine in contrast to the BRAF
V600E
 negative charge 
substitution: this altered distribution of charged residues within the activation 
segment implies augmented in vitro kinase activity (~160 fold higher than 
BRAF
wt
), although at a much lower level compared with BRAF
V600E
, and ERK 
stimulation [130].  
V600M and V600A (T1799C) mutations has been reported in other tumors such 
as melanoma and prostatic adenocarcinoma but, to the best of our knowledge, the 
result of substitutions of these uncharged nonpolar amino acid, methionine and 
alanine, for the uncharged nonpolar amino acid valine on BRAF kinase activity 
has not been tested [118, 152, 153].  
 
1.4.6 Other BRAF
 
mutations in exon 15 
Many cancer-associated mutations described in BRAF cluster to the glycine-rich 
loop and the activation segment, the two regions of the kinase domain that are 
responsible for trapping BRAF in the inactive conformation (Fig. 1.15) [126].  
Among BRAF exon 15 mutations that do not involve the “hot spot” codon 600, 
BRAF
E586K
 has been identified in ovarian cancer and melanoma [134, 154]. 
Glutamic acid 586 is highly conserved in RAF family of proteins being found at 
the corresponding position in all RAF orthologues and paralogues. This residue is 
located outside of the P loop and DFG motif on the opposite surface of the kinase 
domain from the DFG motif, thus is not involved in stabilizing the glycine-rich 
loop/activation segment interaction. E586 is part of a large surface responsible for 
the kinase autoinhibition through a potential intramolecular interaction with the 
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N-terminal domain probably disrupted by its mutation. The substitution of this 
negatively charged amino acid for the positively charged lysine, BRAF
E586K
, 
produces an high activity mutant (~130 fold kinase activity higher than BRAF
wt
) 
that stimulates strong constitutive ERK signaling in COS cells [118, 126, 130, 
134]. 
Another mutation in exon 15, BRAF
G593D
, has been described in colorectal cancer 
and, along with BRAF
V600E
 mutation, in a follicular variant papillary 
microcarcinoma but the significance of this mutation remains uncertain and 
requires further studies [45, 155].  
Mutations that occur at aspartic acid 594 (D594) cause in BRAF (as in other 
kinases) inactivation and thus these cancer mutants cannot phosphorylate MEK, 
activate CRAF, or stimulate cell signaling [130, 146]. Indeed, the carboxy oxygen 
of this highly conserved residue (the “D” of the DFG motif) plays a critical role in 
chelating Mg
2+
 and stabilizing ATP binding in the catalytic site [124]. These 
mutants therefore appear catalytically and biologically inactive: many mutants 
have been found in human cancer such as BRAF
D594N 
in melanoma [154, 156, 
157]. 
A mutation replacing alanine 598 with valine was identified in a follicular variant 
of papillary thyroid carcinoma (PTC FV). BRAF
A598V
 induces local perturbation 
of the protein structure that may explain the up-regulation of the BRAF kinase 
activity and its MAPK downstream signaling factors such as ERK and MEK 
observed by functional analysis. Indeed, functional studies in vitro revealed that 
BRAF
A598V
 leads to up- regulation of BRAF kinase activity with similar ERK 
activation in both BRAF
A598V
 and BRAF
V600E
 mutations [158]. 
As previously discussed, threonine 599 is the major activation segment 
phosphorylation site [132]. Replacement of threonine 599 with isoleucine strongly 
activates BRAF probably because the bulky side chain of isoleucine disrupts the 
inactive conformation of the activation segment similarly to what happens during 
threonine 599 phosphorylation. BRAF
T599I 
heterozygous mutation has been 
described in melanocytic nevi and melanoma lesions where coexistence of 
BRAF
V600E
 and BRAF
T599I
 mutations was also observed in a specimen [153, 159]. 
According to the functional analysis by Wan and colleagues, it is an intermediate 
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activity kinase mutant (~30 fold higher than BRAF
wt
) harboring much lower 
kinase activity compared with BRAF
V600E 
that increases ERK signaling in COS 
cells and causes the transformation of NIH3T3 cells [130].  
As previously discussed, another common BRAF mutation reported in papillary 
thyroid carcinomas (PTC FV), in benign follicular adenomas and a case of 
classical follicular thyroid carcinoma is BRAF
K601E
 [64, 96, 141, 143, 144]. It was 
also found in other tumors such as melanoma and colorectal carcinoma [160, 
161]. It is a single nucleotide substitution in the first nucleotide position 
(A1801G) in codon 601of BRAF gene changing a lysine for a glutamate. 
BRAF
K601E
 is a high activity kinase mutant (~140 fold higher than BRAF
wt
) and 
greatly increase ERK and NFκB signaling, and the transformation of NIH3T3 
fibroblasts [130, 146]. Lys601 has an important role in ligand activity, selectivity 
and protein stabilization, proposing an explanation of the observed strong kinase 
activation for the BRAF
K601E
 mutated form [162]. 
Heterodimerization may play a pathophysiological role in cancer: less frequent 
mutations that cause impaired BRAF kinase activity, such as BRAF
G596R
, cannot 
stimulate efficient activation of MEK, but can stimulate CRAF activity, which 
then activates MEK. Therefore, the ability of low-activity BRAF mutants to 
activate the ERK pathway is dependent on CRAF protein [130].  
The transactivation is obtained by low-activity BRAF mutants found in cancer 
merely as a result of the formation of a heterodimer between the mutant BRAF 
and CRAF. 
While physiological heterodimerization is induced by RAS activation, oncogenic 
BRAF mutants constitutively dimerize with CRAF [128, 163, 164]. 
Among small in-frame insertions or deletions surrounding codon 600 can be 
mentioned V599lns, VK600-1E, V600D + FGLAT601–605ins and T599I-
VKSR(600-603)del and T599I+V600delinsAL [165-171]. 
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Figure 1.15. Some cancer-associated BRAF mutations. BRAF amino acids conserved in ARAF and CRAF 
are shown by a dot. The yellow bars indicate phosphorylation sites. DFG motif/activation segment is partly 
included in exon15 (codon 582 to 620). BRAF mutated residues in cancer are shown in bold, with the amino 
acid substitutions above the sequence. Activating substitutions are shown in green, those that impair BRAF 
kinase activity in red, and untested in blue. Mutated residues outside these core regions are shown below the 
schematic [118]. 
 
1.4.7 The role of BRAF mutation in the initiation and progression 
of PTC 
The high frequency and specificity of BRAF
V600E
 mutation suggest that this 
mutation may play a fundamental role in the initiation of PTC tumorigenesis. This 
idea was supported by clinical findings such as high prevalence of BRAF
V600E
 in 
mPTC and by the results of experiments in thyroid follicular cells and in 
preclinical mouse models [96, 108, 111, 140, 172]. 
BRAF
V600E
 was shown to induce transforming features in thyroid follicular cells in 
culture, such as up-regulation of chemokines and their receptors which in turn 
stimulate proliferation and invasion [173]. Thyroid-induced expression of 
BRAF
V600E
 in transgenic mice, a model that better reflect non-hereditary human 
thyroid cancers, leads to the development of tumors with histological features that 
recapitulate the phenotype of BRAF-mutated PTC in humans [174, 175]. 
Therefore, BRAF
V600E 
mutation may represent the first hit or an early event in 
thyroid tumorigenesis.  
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However, sometimes BRAF mutation may be preceded by other genetic 
alterations occurring in already developed PTC as suggested by the observation 
that BRAF
V600E
 can be detected in lymph node metastasis but not in the 
corresponding primary tumors [176]. Moreover, papillary thyroid carcinoma with 
the BRAF
V600E
 mutation often presents with extrathyroidal invasion, lymph node 
metastasis, and advanced tumor stage [171, 177]. 
This finding are consistent with a role of BRAF
V600E
 mutation in facilitating the 
metastasis and progression of PTC in lymph nodes as evidenced by experiments 
in preclinical models: PTC induced in transgenic mice also undergo 
dedifferentiation and become more aggressive, suggesting a role in tumor 
progression and recapitulating the association of BRAF mutation in PTC with a 
poorer prognosis [175]. 
Some reports of the presence of BRAF mutation in both the differentiated PTC 
components and the poorly differentiated components in PDC and ATC of the 
thyroid suggest that BRAF mutation occurs early in the tumorigenesis and has also 
a role in disease progression [140, 178].  
 
1.4.8 BRAF in the diagnosis of PTC 
Thyroid nodules may be found by palpation in 4-7% of the general population, 
and this prevalence may approach 60% using high-resolution ultrasonography 
(USG), however, only a small proportion of these nodules is malignant [179].  
The most reliable diagnostic test for thyroid nodules is Fine-needle aspiration 
(FNA) with cytological evaluation, which establishes the definitive diagnosis of a 
benign or malignant lesion in the majority of cases. However, a conclusive 
diagnosis can’t be obtained by use of FNA in some cases that are diagnosed as 
indeterminate for malignancy. In 2011, a meta-review of 11 large studies from the 
USA published between 2002 and 2010, showed that a median of 72% (range 62-
85%) of FNA were diagnosed as benign, 5% (1-8%) were malignant, 17% (10-
26%) were indeterminate, and 6% (1-11%) were non-diagnostic. Among patients 
with FNA diagnosed as indeterminate by cytology who underwent surgery, a 
median of 34% (range 14-48%) had a malignant lesion. Since this occurrence is 
too high to recommend watchful waiting, the United States National Cancer 
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Institute (NCI) sponsored a State of the Science Conference in 2007 in Bethesda, 
to review diagnostic terminology and morphological criteria for cytological 
diagnosis of thyroid lesions. The Bethesda classification further divided the 
general category of indeterminate cytology into three subcategories: atypia of 
undetermined significance or follicular lesion of undetermined significance, with 
malignancy in 5-10% of cases; follicular neoplasm or suspicious for follicular 
neoplasm, with malignancy in 20-30% of cases; and suspicious for malignancy, 
with malignancy in 50-75% of cases [180, 181]. 
New preoperative diagnostic approaches for such nodules and for those 
cytologically inadequate are needed: a number of studies have shown that 
molecular testing of FNA samples to guide surgery or watchful waiting is helpful 
for the improvement of the accuracy of cytologic diagnosis of thyroid nodules [6, 
182]. In Figure 1.16 is depicted the potential clinical management of patients with 
thyroid nodules on the basis of a combination of cytological examination and 
molecular analysis.  
  
 
Figure 1.16. Diagnostic utility of molecular markers. FNA, fine-needle aspiration. 
In this potential model of clinical management of patients with thyroid nodules combining cytological 
examination and molecular analysis, patients harboring nodules positive for mutations (high risk of cancer) 
are treated by total thyroidectomy. Patients harboring nodules with an indeterminate diagnosis on cytology 
and negative for mutations might require a repeated FNA and diagnostic lobectomy, although follow-up 
might be recommended for some of these patients, particularly those with the cytologic diagnosis of atypia of 
undetermined significance/follicular lesion of undetermined significance. Molecular testing of nodules found 
to be negative for malignancy by cytology may be useful to decrease the rate of false-negative cytologic 
results [6]. 
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Most studies have explored the diagnostic role of BRAF mutation. Molecular 
testing of BRAF
V600E
, complementary to cytology, significantly improves FNA 
diagnostic accuracy of thyroid nodules.  
Molecular analysis of BRAF
V600E
 in 2766 FNA specimens has been performed in 
several prospective and retrospective studies, and also in studies of research (FNA 
performed on surgically removed thyroid glands) reviewed by Nikiforova and 
Nikiforov. In 580 out of the 581 BRAF
V600E
 nodules detected, the final 
histopathological finding was papillary carcinoma, with a false-positive rate of 
0.2%. A significant proportion (15-39%) of BRAF
V600E
 FNA specimens in these 
studies were indeterminate or nondiagnostic by cytology and several FNA 
samples with benign cytology but positive for BRAF
V600E
 were found to be 
papillary carcinomas after surgery [7]. 
BRAF
V600E
 is highly specific to PTC and false-positive tests have been rarely 
reported: to the best of our knowledge, there are only 7 cases of false-positive 
BRAF testing documented in the literature. The first report, the case reported also 
in the meta-analysis mentioned above, was from Korea, where the BRAF mutation 
is highly prevalent, and describes a benign BRAF positive nodule 
histopathologically diagnosed as atypical nodular hyperplasia. The authors 
supposed that the atypical hyperplasia could have been a premalignant lesion 
[183]. 
Further cases of indeterminate BRAF-positive FNAs that were benign on final 
surgical pathology, were assayed using dual-priming oligonucleotide (DPO)-
based multiplex polymerase chain reaction, which can detect BRAF
V600E
 in 2% of 
cells within a population of wild-type cells. The authors speculated that the false-
positive results were a result of setting the positive cutoff as low as possible [179, 
184, 185]. 
The biggest diagnostic improvement can be achieved by testing FNA samples for 
a panel of mutations rather than for a single mutation. The 2009 Revised 
American Thyroid Association (ATA) Management Guidelines for Patients with 
Thyroid Nodules and Differentiated Thyroid Cancer recommend the use of 
molecular markers, such as BRAF, RAS, RET/PTC, and PAX8/PPARγ, to help the 
management of patients with indeterminate cytology [7, 186]. 
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The current data on BRAF testing support its ancillary use to routine cytologic 
analysis: the development of cost-effective analyses may provide the driving force 
for widespread implementation of preoperative BRAF testing on thyroid FNA 
samples.  
 
1.4.9 The prognostic utility of BRAF 
Molecular testing of preoperative thyroid FNA samples and surgically removed 
thyroid tumors may play an important role in tumor prognostication. Molecular 
markers may improve the identification of tumor harboring a potential for more 
aggressive disease course and therefore requiring more extensive initial surgery, 
more aggressive treatment with adjuvant therapies and more frequent follow-up 
[186].  
BRAF
V600E
 mutation is generally accepted as a reliable prognostic marker for 
papillary carcinoma. Patients with BRAF
V600E
 positive papillary thyroid cancers 
detected preoperatively may benefit from more extensive initial surgery. In fact, 
BRAF
V600E
 has been associated in many studies with aggressive histopathologic 
features of papillary carcinoma, including extrathyroidal extension, 
multicentricity, lymph-node or distant metastases and more advanced stage at 
presentation. 
Moreover, BRAF
V600E
 in PTC has been associated with an increased risk of 
palpable nodal recurrence and the need for reoperative surgery [142, 187-189].  
Patients with BRAF
V600E
 positive PTCs have also an increased chance of treatment 
failure of recurrent disease. These tumors show a decreased response to 
radioiodine treatment probably due to BRAF mutation-promoted loss of the 
expression of thyroid iodide-handling genes, including the gene for sodium iodide 
symporter (NIS), a thyroid-specific basolateral plasma membrane glycoprotein, 
involved in active transport of iodide into the thyroid follicular cells [59, 190].  
The evidence for causality is supported by the fact that in vitro cessation of 
BRAF
V600E
 expression restored the expression of important genes involved in 
iodide metabolism that had previously been silenced by the inducible expression 
of BRAF
V600E
 [191]. The mechanism through which BRAF
V600E
 induces NIS 
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repression relies on the activation of an autocrine transforming growth factor β 
(TGF β) loop. BRAF-induced activation of TGF β and subsequent activation of 
the SMAD signaling pathway leads to NIS repression in thyroid cancer [192]. 
Therefore, BRAF
V600E
 also predisposes to tumor dedifferentiation. These less 
differentiated tumors with reduced ability to trap radioiodine are challenging to 
manage as anatomical localization of recurrences cannot be assessed and 
treatment with ablative doses of radioiodine is not effective. An increased dose of 
radioiodine for initial postoperative treatment, lower levels of suppression of TSH 
(achieved by administering a supraphysiologic dose of thyroxine to the patient) 
and closer postsurgical follow-up has been suggested for patients with BRAF-
positive cancer [78, 171, 193]. 
These findings suggest that knowledge of BRAF mutation status can be used for 
more accurate risk stratification and management of PTC, from preoperative 
planning of initial surgical scale to postoperative decisions. However, BRAF
V600E
 
mutation is found in ~45% of papillary carcinomas, whereas less than 10-15% of 
these tumors show an aggressive clinical behavior [6].  
Therefore, it is probable that additional factors can modify the outcome of patients 
with BRAF
V600E
 positive tumors, such as age. In a study was observed that, even if 
BRAF
V600E
 mutation and aggressive histology characteristics are equally present 
in younger and older (≥ 65 years) patients, the association between BRAF 
mutation and increased risk of tumor recurrence is limited to older patients [194]. 
Moreover, not all BRAF
V600E
 positive papillary carcinomas are aggressive, but 
also not all aggressive papillary carcinomas carry this mutation [7]. 
Although the correlation between the BRAF mutation and more aggressive PTC 
prevail in most reports, many studies failed to confirm the association between the 
BRAF mutation and high-risk clinicopathological factors or poorer outcome [106, 
195-197]. Discordant results concerning BRAF
V600E
 mutation prognostic 
significance may be due to heterogeneity in PTC at the molecular level or 
overlapping phenotypes from different genetic alterations [198].  
Some studies suggested that BRAF
V600E
 is associated with aggressive features 
even in papillary thyroid microcarcinomas. This mutation in mPTC correlates 
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with either high rate of extrathyroidal tumor extension or lymph node metastasis 
or both of these features [111, 199-201]. 
Recently, Niemeier and colleagues suggested that a combination of 
histopathological features and the BRAF status was superior to pathology alone 
for clinical risk stratification of papillary thyroid microcarcinoma, allowing better 
prediction of extrathyroid tumor spread [112, 202].  
Thus, BRAF mutational status may be helpful, in conjunction with conventional 
clinicopathological risk factors, in those cases where clinicopathological criteria 
alone would otherwise be unreliable in defining the risk stratification and 
management of PTC [6, 193].  
 
1.4.10 BRAF as a therapeutic target for PTC  
Differentiated thyroid carcinoma, specifically papillary and follicular thyroid 
carcinoma, account for more than 90% of all thyroid malignancies and have 
generally a favorable prognosis with 10 years survival in excess of 90%. Although 
mortality from differentiated thyroid cancer is low, disease recurrence is high in 
some subgroups of patients, 20-30% or even higher. An accurate assessment of 
the risk of individual patients is important in order not only to guarantee a 
treatment that minimizes chance of progression or recurrence, but also that has a 
good balance between benefits and harms [181, 203, 204]. 
Most of patients with differentiated thyroid carcinomas (85%) are cured with 
surgery (preferentially total thyroidectomy), radioactive iodine and TSH 
suppression. Disease recurrence usually occurs in the neck: the best treatment for 
these tumors is surgical with potential further radioactive iodine [205]. Metastatic 
thyroid cancer is treated with radioactive iodine if the metastases are radioiodine 
avid. However, about 5% of patients will develop more aggressive tumors: these 
patients harboring metastatic disease which fails to respond to radioactive iodine 
will eventually die of their disease [181]. Refractory disease is an advanced 
disease characterized either by the presence of at least one tumor focus without 
any uptake of radioiodine or by progression of the disease during the year after a 
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radioiodine treatment course. This aggressive behavior occurs more frequently in 
older patients, in those with large metastases or with poorly differentiated thyroid 
cancer. It shows a median survival after the discovery of distant metastases 
ranging from 3 to 6 years [206]. 
Cytotoxic chemotherapies for advanced or metastatic non-iodine avid thyroid 
cancers show no prolonged responses and in general have fallen out of favor. 
Indeed, traditional cytotoxic chemotherapies such as doxorubicin, taxol, and 
cisplatin are associated with a 25-37% partial response rate with rare complete 
remission, high toxicity and short duration of responses [205].  
Given the generally poor outcomes associated with cytotoxic chemotherapy, 
patients with progressive or symptomatic metastatic thyroid cancer that is 
considered radioiodine refractory should be considered for treatment on a clinical 
trial with novel targeted therapies [186].  
Discoveries about the pathophysiological basis of advanced thyroid cancer, such 
as the identification of specific oncogenic mutations that appear to be early 
genetic events in DTC and understanding the role of intercellular signaling 
between the tumor cell and the surrounding tumor microenvironment, led to 
development of novel antineoplastic therapies [207]. An important development 
was recognition of processes facilitating tumor growth, reflecting either normal 
(such as hypoxia-inducible angiogenesis) or abnormal (such as epigenetic 
modifications of chromosomal DNA and histones) adaptations. Angiogenesis is 
critical in supporting tumor cell growth and metastasis, supplying nutrients and 
oxygen, removing waste products, and facilitating distant metastasis [208]. A key 
proangiogenic factor is vascular endothelial growth factor (VEGF), that binds to 
two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR) 
involved also in MAPK signaling triggering [209]. In PTC, the intensity of VEGF 
expression correlates with a higher risk of metastasis and recurrence, a shorter 
disease-free survival, and BRAF mutation status. Indeed, BRAF
V600E
 positive 
PTCs tend to have higher expression of VEGF. Since the level of VEGF 
expression was shown to correlate with tumor size, extrathyroidal invasion, and 
stage, high levels of VEGF expression may be related to poorer clinical outcome 
and recurrence in BRAF
V600E
 PTC [198, 210]. 
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The high prevalence and prognostic significance of the BRAF
V600E
 mutation in 
PTC make it an interesting target for the development of molecular therapeutic 
options. As previously discussed, one reason for a poorer prognosis of patients 
with BRAF
V600E
 mutated PTC is the resistance to the conventional radioiodine 
adjuvant therapy because this BRAF mutation promotes the loss of the expression 
of thyroid iodide-handling genes, such as the gene for sodium iodide symporter 
(NIS) [190]. It was shown that inhibition of tyrosine kinase-activated pathways, 
using compounds that block receptor kinase activity directly or that inhibit the 
activity of downstream signaling kinases, induces thyroid cancer cell death in 
vitro and in vivo in preclinical mouse models [177, 211, 212].  
The various small molecule inhibitors of activated BRAF serine/threonine kinase 
that have been developed are assigned to different categories, type I and type II, 
on the basis of their mechanism of action. In particular, they can selectively bind 
kinases with different conformation of the conserved DFG motif. 
Type I tyrosine kinase inhibitors (TKIs) bind to a kinase in its active (“DFG-in”) 
conformation forming interactions with the hinge region and ATP binding site of 
the protein.  
Type II inhibitors use the ATP binding site and an adjacent hydrophobic pocket 
created by the activation loop with the DFG motif being in an “out” conformation 
[130, 213, 214].  
A number of drug candidates targeting BRAF
V600E
 have entered clinical trials in 
recent years. Some of them, such as vemurafenib and dabrafenib, type I inhibitors, 
have shown clinical efficacy [214]. 
Type II inhibitors (such as sorafenib) were the first compounds introduced into the 
clinic for cancer therapy, however type I inhibitors may provide the necessary 
specificity to target successfully mutant BRAF kinases [215]. 
Sorafenib (BAY 43-9006, Nexavar) was the first ligand to be crystallized with 
BRAF and was designed as inhibitor active against both BRAF in its inactive 
conformation and CRAF (Fig. 1.17) [130]. Targeting BRAF in melanoma using 
Sorafenib has not been clinically effective [216-218]. 
Further studies suggested that its effects might not be mediated through BRAF 
inhibition, but through off-target effects. Using drug-resistant versions of 
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oncogenic BRAF generated by mutating the gatekeeper residue, sorafenib still 
inhibited the growth of tumors driven by the mutant protein [219]. Therefore, the 
failure of sorafenib to result in significant objective responses in BRAF-mutant 
melanoma in clinical trials has been interpreted as consistent with the non-BRAF 
mediated mechanism of action of the drug [220]. It was later shown that sorafenib 
mediates antitumor effects in renal cell cancer (RCC) independently of its ability 
to block BRAF
V600E
 signaling [219]. It was eventually approved for the treatment 
of RCC and unresectable hepatocellular carcinoma (HCC). The efficacy in these 
cancers is believed to be due to inhibition of other kinases such as VEGFR2, KIT, 
and Flt-3 [214]. Thus, while initially considered a selective RAF kinase inhibitor, 
sorafenib is a multikinase inhibitor that targets several receptor tyrosine kinases 
such as human VEGF receptors (VEGF-R) 1 to 3, PDGF receptor, and RET [221, 
222]. The results of a recent meta-analysis suggest that sorafenib has only a 
modest effect in patients with radioiodine-refractory differentiated thyroid cancer 
and shows also a high incidence of adverse effects that may affect the quality of 
patients’ life [223]. 
 
Figure 1.17. Type II inhibitors of BRAF [214].  
 
Type I inhibitors with preferential binding to the kinase domain of BRAF in the 
active conformation demonstrated greater inhibitory potency against the 
BRAF
V600E
 mutant kinase than the wild-type [214].  
Vemurafenib (PLX4032, RG7204, Zelboraf) is a potent kinase inhibitor of 
BRAF
V600E
. Along with its sister compound PLX4720, vemurafenib was 
identified through a structure-guided discovery approach optimized for binding to 
the mutant kinase (Fig. 1.18) [224].  
45 
 
In preclinical models of melanoma, vemurafenib inhibited proliferation and ERK 
phosphorylation in cell lines bearing activating BRAF mutations in a dose-
dependent manner, but no inhibition was noted in wild-type cell lines. 
Vemurafenib also potently inhibited proliferation of melanoma cell lines 
expressing other codon 600 BRAF mutations (V600D, V600K, and V600R) and 
showed potent activity in several human BRAF
V600E
 positive melanoma xenograft 
models [225]. 
However, MEK and ERK phosphorylation was unexpectedly increased in cell 
lines containing upstream mutations in RET/PTC or RAS with wild-type BRAF. 
This paradoxical signaling cascade activation by RAF inhibitors is likely due to 
paradoxical transactivation of dimerized RAF kinases. Drug binding to one 
member of RAF homodimers (CRAF/CRAF) or heterodimers (CRAF/BRAF) 
inhibits one protomer, but results in transactivation of the drug-free protomer. In 
BRAF
V600E
 tumors, RAS is not activated, thus transactivation is minimal and ERK 
signaling is inhibited in cells exposed to RAF inhibitors. Moreover, RAF 
inhibitors do not inhibit ERK signaling in cells that coexpress BRAF
V600E
 and 
mutant RAS [226]. 
In a first phase I study, treatment of metastatic melanoma with vemurafenib in 
patients with BRAF
V600E
 mutated tumors resulted in complete or partial tumor 
regression in the majority of patients. This clinical efficacy drastically contrasts 
with a complete absence of clinical response among those lacking the BRAF
V600E
 
mutation underscoring the importance of the appropriate molecular target [227]. A 
randomized phase III trial demonstrated improved rates of overall and 
progression-free survival in patients with previously untreated metastatic 
melanoma with the BRAF
V600E
 mutation compared with dacarbazine, leading to 
the drug’s approval in the USA (2011) and in Europe (2012) [228].  
The recent approval of vemurafenib for patients with advanced melanoma 
harboring the BRAF
V600E
 represents the first FDA approval of a drug and a 
companion diagnostic mutation test to determine patient eligibility for treatment. 
The approved test only documents the presence of the V600E variant, however, 
assessing other BRAF mutations (such as V600K and V600D) and mutations in 
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other genes may have a more extensive impact on patient management and may 
be relevant to understand treatment resistance [229].  
If a mutation is predictive of a drug response in one form of tumor then there may 
be some likelihood that the same drug could affect tumors from other origins with 
the same mutation. However, this hypothesis requires formal testing because the 
presence of a specific mutation may have different clinical implications depending 
on the origin of tumoral tissue. In fact, this intertumor variation is found in 
sensitivity to vemurafenib that is efficient both in BRAF
V600E
 mutated melanoma 
and ovarian cancer but not in BRAF
V600E
 mutated colorectal cancer [228-231]. 
This could be a result of feedback up-regulation of epidermal growth factor 
receptor (EGFR) after BRAF
V600E
 inhibition in epithelial colorectal cancer cells 
but not in melanoma cells, which are derived from the neural crest and have lower 
basal EGFR expression [230]. 
In preclinical studies in PTC, vemurafenib and PLX4720 were shown to block 
cellular proliferation of multiple BRAF
V600E
 mutant cell lines mimicking the 
experience with melanoma. Both compounds inhibited the proliferation of 
BRAF
V600E
 mutant cell lines, but not normal thyrocytes. MEK and ERK 
phosphorylation was also decreased upon vemurafenib and PLX4720 treatment in 
BRAF mutant thyroid carcinoma cells but not in normal thyroid cells or in cell 
lines harboring mutations of RAS or RET/PTC1 rearrangements. However, 
neither proliferation nor downstream kinase phosphorylation could be completely 
inhibited despite maximum drug concentrations, and feedback down-regulation of 
ERK phosphatases was suggested as a potential mechanism. 
Vemurafenib and PLX4720 treatment induced a G1 block and altered expression 
of genes involved in the control of G1-S cell-cycle transition in a BRAF mutant 
cell line, without evidence of cytotoxicity of treatment. In a xenograft model in 
nude mice treated with vemurafenib, BRAF mutant tumor growth was slowed but 
not completely blocked and was associated with reduced MEK and ERK 
phosphorylation [232]. 
A tumor volume reduction was also observed in BRAF mutant xenografts treated 
with PLX4720. Furthermore, the tumors treated with PLX4720 were markedly 
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less invasive and contained increased nuclear localization of thyroid-specific 
transcription factors [233].  
Vemurafenib was tested in a phase I trial in three patients with BRAF mutated 
metastatic DTC. The recently published results showed that among the three 
patients, one had a confirmed partial response with reduction of pulmonary target 
lesions by 31%, and the duration of response was 7.6 months before the disease 
progressed in the lungs and the bones. The time to progression was 11.7 months. 
The other two patients had stable disease, and the time to progression was 13.2 
and 11.4 months, respectively. Two of the patients eventually died of their 
disease, one of whom had developed anaplastic transformation about one year 
after discontinuing vemurafenib. On the basis of these results, a phase II trial of 
vemurafenib has recently been initiated in patients with progressive metastases 
from BRAF
V600E
 mutant PTC [215, 234]. 
Dabrafenib (GSK2118436) is a potent ATP-competitive inhibitor of BRAF kinase 
and is selective for mutant BRAF (Fig. 1.18). It inhibits several of the codon 600 
variants of BRAF, including V600E, V600K and V600D [215]. In a first-in-
human dose escalation phase I trial, efficacy was studied in patients with BRAF 
mutated tumors, including those with other BRAF mutations in codon 600. 
Patients were divided in three cohorts: metastatic melanoma, melanoma with 
untreated brain metastases, and non-melanoma solid tumors. In patients with 
BRAF mutant non-melanoma solid tumors, apparent antitumor activity was 
observed in papillary thyroid cancer, gastrointestinal stromal tumor, non-small-
cell lung cancer, ovarian cancer, and colorectal cancer. In patients with BRAF 
mutant melanoma treated with dabrafenib partial response was recorded in 69% of 
patients, including those with V600K and V600G mutations, and significant 
tumor reductions were seen in 90% of patients with intracerebral metastases. Of 
the 9 patients with BRAF mutated PTC included in the trial, 3 (33%) achieved 
partial response [235]. 
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Figure 1.18. Type I inhibitors of BRAF [214].  
 
Among melanoma patients, acquired resistance to vemurafenib therapy has been 
observed, associated with a variety of proposed mechanisms other than secondary 
BRAF mutations, such as RAS activation or enhanced signaling through CRAF 
[236-238].  
As BRAF inhibitor therapy evolves also for DTC, it is likely that similar 
mechanisms of resistance will emerge, suggesting that monotherapies represent a 
first step in improving patient outcomes but can be insufficient to eradicate 
advanced and metastatic disease. Probably the identification of rational ways to 
combine individual therapies will be necessary for more effective outcomes. A 
strategy involves individual targeted therapies merged together or with selected 
traditional cytotoxic agents; another one suggest a sequential inhibition along the 
MAPK pathway, blocking both BRAF and MEK simultaneously in order to 
overcome acquired resistance to monotherapy with BRAF inhibitors observed in 
melanoma, mediated by reactivation of MAPK signaling [215].  
Also in the field of thyroid cancer research individual therapies are being 
combined together in order to improve patient survival. Examples include the 
demonstration of synergistic effects of the BRAF
V600E
 inhibitor vemurafenib 
combined with the AKT inhibitor MK2206 in thyroid cancer cells harboring both 
the BRAF
V600E
 and PIK3CA mutations [239].  
Another possible approach, based on observations in BRAF
V600E
 thyroid cancer 
cell lines, include combining BRAF with HER kinase inhibitors. A study suggests 
that thyroid cancer cells with mutant BRAF are resistant to vemurafenib compared 
with melanoma because this inhibitor induces the de-repression HER3 
transcription, diminishing the antitumor effects of RAF inhibitors. The 
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combination of vemurafenib with the HER kinase inhibitor lapatinib sensitizes 
BRAF mutant thyroid cancer cells to inhibitors [215, 240].  
Novel molecular-targeted therapies seem to hold great promise for radioiodine-
refractory and surgically inoperable thyroid cancers and are likely to become part 
of the standard treatment regimen for patients with thyroid cancer in the future. 
 
1.4.11 Methods for detection of BRAF molecular alterations 
The identification of specific mutations driving a cancer is important both for the 
development of targeted therapies and for screening of patients for personalized 
treatment. 
The choice of techniques for clinical detection of molecular alterations in thyroid 
cancer specimens relies on the sample type available for analysis and the mutation 
types.  
BRAF mutational analysis used in diagnostics to identify clinically relevant 
mutations can be performed using many different methods, however, the 
sensitivity and specificity of mutation detection varies for different methods used 
for testing [241].  
Sanger sequencing is considered the “gold standard” technique for mutation 
detection. However, although it permits a screening of the entire nucleotide 
sequence of the target region, it is low throughput (mainly due to cost constraints), 
requires several distinct steps leading to higher contamination risk and lacks the 
sensitivity to detect small but significant subpopulations of tumoral cells [242, 
243]. Indeed, it can only detect with sufficient accuracy mutations present in at 
least 10% of mutated DNA, corresponding to 20% of neoplastic cells with a 
heterozygous mutated allele [244, 245].  
Analytic sensitivity of assays is a very important feature because tumoral cells 
may represent only a fraction of the available specimen. In fact, many routine 
samples contain large numbers of non-neoplastic reactive or inflammatory cells 
that can lead to false negative results. Therefore, microdissection of histologic 
specimens prior to DNA extraction is usually necessary to enrich for neoplastic 
cells in order to avoid false negative results. This tumor cell enrichment is not 
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feasible in the case of FNA specimens [245]. Furthermore, material available for 
molecular analysis from cytological specimens and FNAs may be restricted, 
especially when multiple tests are performed. 
Moreover, tumors may show considerable heterogeneity in the presence of the 
mutation being targeted because of clonal evolution processes.  
Efforts to enhance sensitivity have produced a variety of methods to detect the 
BRAF mutations based on different approaches but often designed to generate a 
qualitative (positive/negative) result rather than a quantitative result.  
Qualitative assessment of single point mutations in thyroid disease, such as 
mutations at codons 600 and 601 of BRAF, can be achieved using different 
methods including allele-specific PCR, PCR-based single-strand conformation 
polymorphism (PCR-SSCP), PCR-restriction fragment length polymorphism 
(RFLP)-based analysis, PCR-melt curve analysis, PCR hybridization (including 
microarrays) and MALDI-TOF mass spectrometry [246]. 
MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight) mass 
spectrometry and oligonucleotide microarray are high-throughput and automated 
methods, however, can be time consuming and require the use of sophisticated 
platforms not always affordable by pathology laboratories [149, 247]. 
In addition, as previously discussed in section 1.4.8, a dual-priming 
oligonucleotide (DPO)-based multiplex PCR analysis was developed to detect the 
BRAF
V600E
: this assay may detect the mutation in as few as 2% of cells in a FNA 
specimen of thyroid nodules [185]. 
Although allele-specific PCR assays are more sensitive than direct sequencing for 
detecting small numbers of mutant cells, they are limited by low specificity in 
discriminating single-base point mutations with natural DNA primers and by 
design to generate a qualitative result [246].  
Among highly sensitive semi-quantitative molecular approaches to detect 
BRAF
V600E
, an Allele Specific Locked Nucleic Acid quantitative PCR 
(ASLNAqPCR) was designed by our group and is described in section 3.3 [245]. 
Pyrosequencing is another highly sensitive semi-quantitative method that permits 
also to screen BRAF mutations in the entire target nucleotide sequence. In a study 
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by Guerra and colleagues it was used to detect the percentage of BRAF
V600E
 allele 
in genomic DNA of PTC specimens with a cutoff settled at 5% [248]. 
Recently, the development of next-generation sequencing (NGS) methods has 
enabled simultaneous detection of all known clinically relevant mutations in 
different genes as a single test and provides enormous amounts of novel 
information. Despite greater complexity compared with Sanger sequencing or 
alternative methods, next-generation sequencing offers high analytical sensitivity, 
screening of the entire target nucleotide sequence, semi-quantitative evaluation of 
the mutated allele and analysis of many samples in a single run (high throughput) 
thanks to the possibility of performing parallel analysis of a very large number of 
DNA molecules (massive parallel sequencing) [249]. 
454 Sequencing system allows confident calling of low-frequency variations: in a 
well designed and well executed experiment, rare variants with a prevalence of 
1% or less can be analyzed [250]. 
This technological development has permitted the definition of the entire DNA 
sequence of common types of human cancers and is clarifying the extent of 
genetic heterogeneity in cancers, thus opening new possibilities but also practical 
challenges in the clinic (section 1.5.2) [251, 252].  
 
1.5 Tumor heterogeneity 
1.5.1 BRAF mutation and intratumoral genetic heterogeneity 
Genetic and phenotypic variation can be identified in tumors affecting different 
tissue and cell types, in different metastatic tumors from a single patient or in 
individuals with the same tumor type (intertumor heterogeneity). Moreover, 
genetic and phenotypic variation can be also observed within a given tumor 
(intratumor heterogeneity) where populations of genetically distinct subclones can 
intermingle (as shown by subclones 1 and 2 in Fig. 1.19) or be spatially separated 
(as shown by subclone 3) as a result of physical barriers such as blood vessels or 
micro-environmental changes. This subclonal architecture varies dynamically 
throughout the disease course. 
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Genetic and epigenetic variation that results in phenotypic diversity can be found 
also within tumor subclones: intercellular genetic heterogeneity is generated by 
genetic instability, an ubiquitous characteristic of neoplasms fundamental to the 
processes of neoplastic progression [253].  
 
Figure 1.19. Intertumor and intratumor heterogeneity [253]. 
According to Nowell’s classical description of cancer as an evolutionary process, 
parallel to Darwinian natural selection, most neoplasms arise from a single 
mutated cell of origin, and tumor progression results from malignant clonal 
expansion secondary to additional stepwise acquired genetic and genomic 
alterations. Mutagenic processes are essentially non-purposeful and may reflect 
prior exposure to carcinogens, such as radiation exposure for BRAF. Many of the 
genetic and epigenetic alterations observed in neoplasms are selectively neutral 
(passenger or hitchhikers lesions), whereas other alterations confer a selective 
growth advantage (driver lesions).  
Clonal evolution implies the interplay of selectively advantageous lesions, 
selectively neutral lesions, deleterious lesions and lesions that increase the rate of 
other genetic changes (mutator lesions) [254, 255]. Moreover, cancer clone 
genetic diversification and subclonal selection occurs within tissue 
microenvironments that provide both the venue and the determinants of fitness 
selection: changes to the microenvironment change also the fitness effects of these 
lesions [256]. 
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The step wise acquisition of these alterations can result in the emergence of tumor 
subclones with phenotypic advantages such as invasion, proliferation, ability to 
colonize different organs. 
The model of clonal evolution hypothesizes a series of clonal expansions: 
mutations that increase the ratio between rates of cell division of a clone and cell 
death will help the mutant clone to expand in the neoplasm. This subclonal 
dominance or “selective sweep” is the phenomenon of natural selection driving an 
allele to fixation. The spread of a lesion throughout the entire population is called 
“fixation” because, without competing alleles left, natural selection cannot change 
the frequency of the lesion in the population. Not all of the mutations that have 
gone to fixation are advantageous: also neutral mutations can spread to fixation. 
The fixation of neutral mutations can happen through genetic drift, a random and 
slow process or more likely through linkage to a selectively advantageous lesion. 
Since it is unlikely that the same neutral mutation would co-occur (hitchhike) with 
a selectively advantageous mutation across multiple independent neoplasms, the 
expansion of a mutation in many neoplasms is evidence for an advantageous 
mutation [254, 257]. However, if the time until the emergence of a next driver 
mutation in a competitor clone is shorter than the time required for a clone to 
sweep through the neoplasm, parallel clonal expansion is restrained by mutual 
competition (clonal interference). This situation may precede dominance of 
subclones early in cancer development [254]. 
Since 1976, clonal expansions as well as intertumor and intratumor genetic 
heterogeneity have been identified in several tumor types. Subclonal populations 
of mutated cells have been found in metastatic melanoma, esophageal 
adenocarcinoma, breast carcinoma, lung cancer, and colorectal carcinomas [258-
265]. Moreover, the concept that not all tumors cells in primary tumors harbor the 
mutation implies that secondary metastases may or not, and in different amounts, 
retain the original set of mutations of the primary lesions. 
In melanoma, Lin et al. observed by single-cell PCR and sequencing marked 
polyclonality of BRAF mutations in acquired melanocytic nevi: cells with rare 
BRAF mutations, such as BRAF
T599I
, BRAF
V600K 
and BRAF
V600A
, all of which 
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previously described in melanoma lesions, were found in nevi harboring also 
BRAF
V600E
 mutation and BRAF
wt
 cells [153].  
They also found a similar heterogeneity of BRAF mutations in primary 
melanomas in tumors that were wild-type by direct sequencing. They observed 
melanomas that contained tumor with BRAF
wt
 cells, BRAF
V600E
 and other 
activating BRAF mutations (such as BRAF
K601R
 and BRAF
V600M
) in minor 
subpopulations that did not outgrow BRAF
wt
 cells. However, BRAF mutant alleles 
were positively selected during melanoma progression in recurrent primary tumor 
or metastases [152]. 
Yancovitz and colleagues have recently investigated intertumor and intratumor 
heterogeneity in melanoma using detection of the BRAF
V600E
 mutation as a marker 
of clonality by semi-quantitative mutation-specific SNaPshot assay. Heterogeneity 
of the BRAF
V600E
 mutation was observed both among multiple specimens from 
individual patients and within individual melanoma tumor specimens [265]. 
Clonality of the BRAF
V600E
 mutation has been recently analyzed by Guerra and 
colleagues also in papillary thyroid cancer using a semi-quantitative 
pyrosequencing technique. This study has shown that clonal BRAF
V600E
 is a rare 
occurrence in papillary thyroid cancer and is more frequently a subclonal event 
suggesting that usually it is not an early hit during PTC development. 
Indeed, in this study most PTCs were found to have 5%-25% of BRAF
V600E
 
alleles, which corresponds to less than half of the cells within the tumor carrying 
heterozygous mutation [248]. 
The existence of intertumor and intratumor heterogeneity has important 
implications in clinical management. The current approach to molecular 
biomarker testing to inform cancer treatment focuses on interpatient tumor 
heterogeneity. However, intratumor heterogeneity is also clinically relevant 
because the presence of genetically distinct tumor subclones may account for 
resistance to targeted pharmacotherapy. Moreover, the status of predictive 
biomarkers may evolve during tumor progression not only under the selective 
pressure of microenvironment but also under the influence by exposure to cancer 
treatment that leads to the eradication of sensitive clones and emergence of often 
55 
 
pre-existing treatment-resistant subclones in metastatic disease that were present 
at minor frequency in the primary tumor [253].  
As previously discussed, the impact of BRAF
V600E
 on clinical outcome has been 
extensively investigated with conflicting results: the recent finding of subclonal 
BRAF
V600E
 status in PTC may offer an explanation for these inconsistent results. 
In fact, Guerra and colleagues observed that a high percentage of BRAF
V600E
 
alleles is associated with high risk clinicopathological factors and predicts a 
poorer disease outcome. In particular, they found that higher frequency of 
multifocality, extrathyroidal extension, and lymph node metastasis in the tumors 
with percentages of the BRAF
V600E
 allele of 30% or greater than in those 
harboring the BRAF
wt
 allele, although without statistical significance in a reduced 
number of samples [248].  
However, in a study by Gandolfi et al., the occurrence and percentage of the 
BRAF
V600E
 mutated allele was not preferentially associated with the development 
of either distant or lymph node metastases. Approximately 80% of lymph node 
metastases from mutated primary PTCs retained the BRAF
V600E
 mutation and the 
average mutated allele percentage decreased as the tumor progresses from the 
primary site to the lymph node metastatic sites. 
Therefore, the preoperative analysis of BRAF mutational status by semi-
quantitative methods might allow a molecular subtyping of PTCs, even if caution 
is required on the potential clinical application of BRAF
V600E
 mutation as a 
negative prognostic factor [266]. 
 
1.5.2 Clinical implications of intratumoral heterogeneity  
Recognition that intratumor heterogeneity has a role in resistance to targeted 
therapies suggests that an approach shift in therapy is required: it would be worth 
considering that each patient harboring a tumor may harbor genetically distinct 
cancer subclones with different genetic aberrations that may render them resistant 
to specific systemic therapies. Indeed, in metastatic disease, recent studies have 
shown the emergence of treatment-resistant subclones that were present at a minor 
frequency in the primary tumor [251].  
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As previously discussed in section 1.4.11, the possibility to include the concept of 
intratumor genetic heterogeneity in personalized medicine has been limited by the 
sensitivity of the methodology employed, especially automated Sanger 
sequencing, the principal method employed in clinical laboratories for many years 
[242].  
However, the present stage of technological development in the future will 
probably improve the design of individualized treatment through the use of 
combinatorial therapeutic agents targeting also rare clones in order to reduce the 
chances of the emergence of resistant clones (Fig. 1.20) [267].
  
 
 
Figure 1.20. Adjuvant targeted therapy of primary tumors with clonal heterogeneity. The present 
situation is targeted therapy on the basis of the dominant clone after surgical resection (A). In the future, 
targeted therapy driven by deep sequencing after surgical resection of the primary tumor will be probably 
directed by the characteristics of both dominant and rare clones, with a combination of therapies (a, b, c) to 
eradicate all clones (B) [267]. 
Next generation sequencing was previously outside the purview of a clinical 
laboratory owing to the cost, high-performance computing capacity and the 
sophisticated bioinformatics expertise that was required for sequence alignment 
and mutation calling. The falling cost of NGS and the recent development of 
bench-top next-generation sequencing instruments, that offer high coverage of 
clinically relevant cancer genes with fast sequencing runs and manageable data 
size without the need for specialized computing, have made this method 
accessible for clinical laboratory. 
Even if NGS offers large-scale nucleotide analysis including whole-genome 
sequencing, whole-exome sequencing and whole-transcriptome sequencing that 
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are essential for discovery projects, targeted sequencing of multiple specific 
genomic regions may offer advance in routine molecular diagnostics of cancer 
[251]. 
In the last few years, clinical laboratories have begun to investigate how to 
employ NGS for clinical testing, as this huge sequencing capacity opens up new 
possibilities for molecular diagnosis that Sanger sequencing technology could not 
offer but also implies challenges in clinical assessment [268, 269].  
Clinical assessment of intratumor heterogeneity has some practical challenges. 
The Next Generation Sequencing Standardization of Clinical Testing (Nex-
StoCT) workgroup recommends for all clinically actionable mutations an 
independent analysis using an alternative method to confirm the mutations found 
before reporting to the treating clinician [270]. 
However, mutation verification can delay the reporting of results to the 
oncologist. Moreover, when NGS identifies a low-frequency mutation, it cannot 
be confirmed by Sanger sequencing due to the limitations of sensitivity of this 
sequencing method. Lastly, when multiple mutations are detected, it’s difficult to 
report clear results to clinicians who have to decide which mutation or mutations 
are clinically overriding. Therefore, the collaborative engagement of clinicians 
and scientists is essential to improve personalized cancer medicine [229, 251].  
In a recent study by Marina N. Nikiforova and colleagues, targeted NGS was 
performed for simultaneous testing for multiple mutations in thyroid cancer using 
a custom mutational panel (ThyroSeq). This panel, proposed to improve the 
accuracy of cancer diagnosis and prognostication in thyroid nodules, provides 
quantitative assessment of mutant alleles. They observed that in PTCs, the vast 
majority of tumor samples (80%) had more than 25% of BRAF
V600E
 mutant 
alleles, corresponding to more than 50% of cells carrying a BRAF
V600E
 
heterozygous mutation. Therefore, they considered BRAF
V600E
 a clonal driver 
mutation in these tumors ascribing the lower abundance of BRAF
V600E
 to a 
dilution of BRAF mutant allele due to some degree of contamination by normal 
stromal, endothelial and inflammatory cells [271]. 
The ability of a single next-generation sequencer to perform simultaneous 
sequencing of short nucleic acid sequences in a massively parallel way allows a 
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laboratory the opportunity to detect multiple genetic alterations in a cost-effective 
manner. This opportunity is of great importance when there are many possible 
causative genes for a specific phenotype. NGS permits not only the analysis of 
many samples in a single run (high throughput), but also high sensitivity of 
mutation detection and semi-quantitative assessment of mutant alleles [268, 269]. 
Thus, NGS can provide new insights into the biology of thyroid cancer and is also 
expected to further improve the accuracy of routine molecular cancer diagnosis 
and prognostication in thyroid nodules. 
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CHAPTER 2 
AIMS OF THE THESIS 
 
At present, the intratumor heterogeneity is a key topic relevant to the field of 
cancer research. Intratumor heterogeneity consists in genetic variations within 
individual tumors. These genetic differences may affect responses to molecularly 
targeted treatments leading to drug resistance. 
BRAF
V600E
 is the most frequent mutation detected in PTC and it is a promising 
target currently being evaluated for the treatment of advanced thyroid cancer. 
Therefore, detecting clonality of BRAF
V600E
 mutation in PTCs is important in 
order to better understand the molecular basis of PTC development and evaluate 
the feasibility of using BRAF
V600E 
specific inhibitors. 
Moreover, assessing the presence of other BRAF mutations in hot spot exon 15 
using novel highly sensitive methods may be relevant to understand thyroid 
tumorigenesis and to inform treatment decisions. 
 
Therefore, this project was undertaken to: 
 
- Aim 1: establish whether the BRAFV600E mutation is present in all tumor 
cells in a given tumor or if it occurs as a subclonal event in papillary 
carcinomas (PTCs), thus establishing how early an event is BRAF
V600E
 
mutation.  
- Aim 2: screen with high sensitivity BRAF mutations in exon 15 in 
histologically benign thyroid tissue of cases with BRAFV600E or BRAFwt 
PTCs in order to identify putative precursor lesions of papillary thyroid 
carcinoma. 
 
In order to reach these goals, two high sensitive semi-quantitative methods 
were used: Allele Specific quantitative PCR (ASqPCR) with Locked 
Nucleic Acid (LNA) primers and 454 Next-Generation Sequencing (NGS).  
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Ethic statement and selection of cases 
All information regarding the human material was managed using anonymous 
numerical codes and samples were handled in compliance with the Helsinki 
Declaration [272]. 
All cases were obtained from the Anatomic Pathology units of Bellaria and 
Maggiore Hospitals (Bologna, Italy) and diagnosed according to the 
histopathological typing of the World Health Organization (WHO) [4]. Stage was 
calculated according to tumor size, lymph node metastasis and distant metastasis 
at the moment of diagnosis (pTNM) designated by American Joint Committee on 
Cancer (AJCC) [53].  
Aim 1. The case study for the first aim of the project was made up of 155 
consecutive formalin fixed and paraffin embedded (FFPE) thyroid specimens of 
PTCs that were analyzed for BRAF
V600E
 mutation by ASLNAqPCR (30 cases 
were also analyzed by 454 NGS).  
Aim 2. For the second aim of the project, 75 histologically benign FFPE thyroid 
specimens from 20 cases with BRAF
V600E
 and 23 from 9 cases with BRAF
wt
 PTCs 
were analyzed by 454 NGS for the possible presence of BRAF mutations in exon 
15. Ten samples with histologically normal thyroid parenchyma were also 
analyzed by 454 NGS. 
During the preanalytical phase of the specimens belonging to the first 
retrospective study, the Hematoxylin and Eosin (H&E) sections from each case 
were observed by a pathologist to select the blocks with the highest proportion of 
PTC neoplastic cells over non neoplastic thyroid cells, inflammation and necrosis.  
For the second project, the blocks carrying benign lesions not associated with 
histologically identifiable tumor cells were chosen for BRAF
 
exon 15 mutational 
screening. Type and number of histologically benign lesions analyzed from 
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BRAF
V600E
 and BRAF
wt
 PTC groups are summarized in Table 3.1. These types of 
histologically benign lesions are described in sections 1.2.1 and 1.3.1. “Atypical 
focus” is defined as a microscopic area with abnormal cells that show cytological 
atypia without the fully developed histologic hallmarks of malignancy. 
 
Type of sample BRAF
V600E
 group BRAF
wt
 group 
Atypical focus 32 5 
Hyperplasia 13 3 
Follicular adenoma 1 3 
Oncocytic follicular adenoma 2 - 
Psammoma body 3 3 
Normal 24 9 
Total 75 23 
 
Table 3.1. Type and number of histologically benign lesions analyzed for possible presence of BRAF 
mutations in exon 15. 
 
Five 10 µm-thick serial sections for each case were cut from the blocks selected 
followed by one H&E control slide that was further reviewed by a pathologist in 
order to verify that the neoplastic or histologically benign areas previously chosen 
were still present and mark these enriched samples for genomic DNA isolation 
(Fig. 3.2).  
 
Figure 3.2. The pathologist review in preanalytical phase. 
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3.2 Genomic DNA isolation and quantification 
The five 10 µm-thick slides were manually dissected with a sterile blade under 
microscopic guidance according to the area marked on H&E. 
Tissues were then deparaffinised by incubation in xylene for 15 minutes at 60°C, 
then washed twice at room temperature with absolute ethanol and digested 
overnight with proteinase K at 56°C. Genomic DNA was then isolated using a 
column based commercial kit (High Pure PCR Template preparation kit, Roche) 
according to manufacturer's instructions and eluted in 65 μl of warmed up Elution 
Buffer. 
The concentration of the genomic DNA extracted was assessed fluorometrically 
using the Quant-iT™ dsDNA HS Assay Kit on a Qubit™ Quantitation Platform 
(Invitrogen).  
 
3.3 Mutational analysis: Allele Specific Locked Nucleic 
Acid quantitative PCR (ASLNAqPCR) 
Allele-specific PCR is a hot spot mutation assay based on positioning the 3-prime 
base of a PCR primer to match a single point mutation allele in order to extend 
only the correctly matched primer under stringent conditions.  
The assay used in this study, called Allele Specific Locked Nucleic Acid 
quantitative PCR (ASLNAqPCR), is based on molecular beacon probe as 
detection system. Molecular beacons (MBs) are single-stranded, fluorophore-
labeled oligonucleotide hybridization probes that form a stem-and-loop (hairpin) 
structure. The loop is complementary to the target sequence, and the stem is 
formed by the annealing of complementary arm sequences that are located on both 
the ends of the probe sequence. A fluorophore, such as fluorescein (Fam), is 
covalently linked to the 5-prime end of the probe and a quencher dye, such as 
Black Hole Quencher
®
-1 (BHQ
®
-1) dye, is covalently attached to the 3-prime 
end. Molecular beacons do not fluoresce when they are free in solution because 
they are in closed loop shape and the proximity of the quencher prevents the 
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fluorophore from emitting light. When the probes encounter a target molecule, 
they form a probe-target hybrid that is longer and more stable than the stem 
hybrid. Hybridization with a target nucleic acid strand opens the hairpin and 
physically separates the reporter from quencher: this conformational change 
allows a fluorescence signal to be emitted upon excitation (Fig. 3.3) [273-275]. 
 
Figure 3.3. Molecular beacon (MB) probe structure and working principle [273]. 
 
The allele specific technique could lead to misprime when performed with natural 
DNA primers leading to inaccurate genotyping. Therefore, primers and beacon 
probes were modified with locked nucleic acids (LNA) to test the presence of the 
BRAF
V600E 
mutation [245]. 
LNA is a bicyclic nucleic acid analogue that contains a 2'-O, 4'-C methylene 
bridge which restricts the flexibility of the ribofuranose ring locking the structure 
into a rigid conformation with enhanced hybridization performance and biological 
stability (Fig. 3.4).  
 
Figure 3.4. Locked nucleic acid (LNA) and DNA base structures. 
 
ASLNAqPCR assay can be performed in any laboratory with real-time PCR 
equipment, doesn’t require post-PCR manipulation (reducing the risk of 
contaminations and material loss), is cost-effective and rapid. The process is not 
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labor-intensive, in fact it requires about 3 hours after DNA extraction including 
about 30 minutes operator time to prepare the PCR reaction and load the plate, 1 
hour and 30 minutes for the real-time run and 5 for data analysis. Moreover, this 
is a semi-quantitative method that gives information about the ratio of mutant and 
wild-type alleles. A limitation of ASLNAqPCR, inherent in all hot spot mutation 
assays, is that it identifies only the targeted mutations [245].  
 
3.3.1 PCR design and conditions 
Both primers and molecular beacon probe for ASLNAqPCR (Table 3.5) were 
designed using Primer3 software (http://frodo.wi.mit.edu/primer3/). Flanked 
molecular beacon arms were designed using the OLIGO 6.0 software reaching a 
temperature between 57°C and 61°C in the stem loop conformation. 
Both primers and molecular beacon probe were modified with LNA as previously 
described by Latorra et al. using a tool on the Exiqon website (www.exiqon.com) 
that performs a melting temperature valuation [276]. 
In the forward primers recognizing wild-type or BRAF
V600E
 alleles, a single LNA 
nucleotide was placed at the 3ʹ terminal position, where the mutation occurs, in 
order to avoid inaccurate genotyping. A universal reverse primer was designed for 
both alleles. The molecular beacon probe was internally LNA-modified allowing 
to maintain high sensitivity and specificity of signal and to avoid false positives 
and primer dimers. Both primers and probe were tested by MFOLD 
(http://www.bioinfo.rpi.edu/applications/mfold/old/dna/) to verify the absence of 
secondary structures that can hamper the annealing to the templates [245]. 
 
Gene Forward Primer Reverse Primer 
Amplicon 
length 
BRAF ASqPCR 
WT 
TAGGTGATTTTGGTCTAGCTACAG+T TTAATCAGTGGAAAAATAGCCTCA 
117 bp 
BRAF ASqPCR 
V600E 
TAGGTGATTTTGGTCTAGCTACAG+A TTAATCAGTGGAAAAATAGCCTCA 
BRAF ASqPCR 
BEACON 
5'-FAM-CCGAAGGGGATC+CAGACAA+CTGTTCAAACTGCCTTCGG-3BHQ-1 -3′ 
Table 3.5. BRAF ASqPCR primers and molecular beacon probe. + precedes LNA nucleotides 
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ASLNAqPCR was performed with reagents from FastStart Taq DNA Polymerase 
kit (Roche) in a final 25 l reaction volume containing: 0.2 mM dNTP mix, 1X 
PCR reaction buffer (with 2 mM MgCl2), 2 mM MgCl2 Solution, 1.25 U of 
FastStart Taq DNA Polymerase, 5 pmol of beacon probe, 1x ROX Reference Dye 
(Invitrogen), 10 pmol of both forward and reverse primers, 15-40 ng of genomic 
DNA from FFPE tissues and molecular biology grade water (UltraPure™ 
DNase/RNase-Free Distilled Water, Gibco) to final volume. Each reaction was 
covered with mineral oil (for molecular biology, light oil; Sigma-Aldrich). 
Real-time PCR was performed using the ABI SDS 7000
TM
 instrument (Applied 
Biosystems) with PCR conditions shown in Table 3.6: the use of a molecular 
beacon probe implies that the plate reading step is annealing. 
 
Step Temperature Time No. of cycles 
Signal normalization 50°C 2ʹ 1 
Initial denaturation/ Enzyme activation 95°C 10ʹ 1 
Denaturation 95°C 30ʹʹ 38 
Annealing 60°C* 30ʹʹ 38 
Extension 72°C 30ʹʹ 38 
Table 3.6. PCR conditions for ASLNAqPCR. *Plate reading step. 
 
A 2.5% agarose gel stained with GelStar™ Nucleic Acid Gel Stain (Lonza 
Bioscience) was performed to confirm the presence of specific PCR products. 
 
3.3.2 Relative quantitation of BRAF
V600E
 mutated allele  
The data analysis was performed using the threshold cycle (Ct) parameter: relative 
mutant allele copy number is determined during the exponential phase of realtime 
PCR using the ΔCt method [277]. If allele specific PCR finds a positive signal for 
the primer specific for the BRAF
V600E
 mutation, the ratio of BRAF
V600E
 mutated 
versus wild type alleles (R) can be calculated with the formula below: 
 
ΔCt = Ct V600E- Ct WT  
R=2 
– ΔCt 
 
% mutated cells= R x 100 
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Samples with a Ct above 36 for the wild type allele were considered failures 
because a mutant allele dropout caused by the low amount of genomic DNA 
cannot be excluded. 
Examples of BRAF
wt 
and BRAF
V600E
 sample amplification plots analyzed by 
ASLNAqPCR are shown in Fig. 3.7. 
 
Figure 3.7. BRAFwt (A) and BRAFV600E (B) sample amplification plots by ASLNAqPCR. 
 
3.3.3 Analytical sensitivity 
The analytical sensitivity of ASLNAqPCR was assessed using serial dilution of 
DNA extracted from OCUT (an undifferentiated thyroid cancer cell line) and 
ARO (an anaplastic thyroid cancer cell line) that are BRAF
V600E
 heterozygous. 
DNA isolated from the cell lines is spiked in a pool of healthy female donors 
DNA (DNA Female pool, Promega) and serially diluted as 50%, 20%, 10%, 5%, 
1%, 0.1%, 0.01% mutant to wild type DNA ratios. The analytical sensitivity of 
ASLNAqPCR, that is the minimal amount of input DNA required to obtain 
reliable mutation detection with this method, is 0.1% (Fig.3.8). This very high 
analytical sensitivity allows quantification of mutated DNA in small neoplastic 
clones [245].  
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Figure 3.8. Amplification plots showing the analytical sensitivity of ASLNAqPCR. Serial dilution of the 
BRAFV600E mutated OCUT cell line DNA in wild type DNA.  
 
3.4 Mutational analysis: 454 Next-Generation Sequencing 
The screening of BRAF
 
mutations in exon 15 in histologically benign thyroid of 
cases with BRAF
V600E
 or BRAF
wt 
PTCs was performed by parallel pyrosequencing 
technology using the 454 GS-Junior
®
 next-generation sequencer platform (Roche) 
according to the manufacturer’s instructions [250].  
The main Next-Generation Sequencing (NGS) technology advantages compared 
with the first generation Sanger sequencing technology are high throughput 
(linked with the possibility of parallel analysis of multiple samples) and reduced 
cost. NGS technologies also merge the possibility to screen for the presence of 
mutations the entire area of interest with the high analytical sensitivity of targeted 
mutation assays. 
The founder company launched 454 Next-Generation Sequencing (454 NGS) in 
2005 and was purchased by Roche in 2007. In late 2009, Roche commercialized 
the GS Junior System, a benchtop 454 sequencing system with simplified library 
preparation and data processing, able to perform 400 bp long sequencing reads in 
10 hours. The distinguishing advantages of 454 Sequencing System are its speed 
and the read length compared with other NGS systems but the cost of reagents is 
higher [278].  
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454 NGS allows the parallel analysis of hundreds of amplicons of the same 
sequence (“reads”) and provides a quantitative estimation of the relative 
abundance of the mutated allele determining the number and percentage of 
mutated reads.  
 
3.4.1 Primers design  
In this study, primers designed for 454 NGS PCR reactions for the preparation of 
the amplicon library (Fig. 3.9) are bi-directional fusion primers made up of three 
parts: a universal sequencing tail, multiple identifiers nucleotide sequences 
(MIDs) and a template specific sequence (Integrated DNA Technologies Inc). 
The 5ʹ-portion is a 25-mer: the sequence is composed of an Adaptor and a “key” 
(shown in blue and red in Fig 3.9 respectively). The Adaptor sequences (A and B) 
are universal sequences involved in binding to the DNA Capture Beads (Lib-A), 
and annealing the emPCR Amplification Primers and the Sequencing Primers. 
The four nucleotide sequencing key “TCAG”, placed at the end of 5ʹ-part of the 
fusion primer, allows the instrument to recognize where the amplicon sequence 
starts.  
Multiplex IDentifiers (MIDs), shown in Fig.3.9 in orange, are “DNA barcodes” 
used to sort each amplicon after the sequencing Run by the data analysis software. 
In a given sequencing Run a specific target sequence is associated with a unique 
pair of MID and therefore is possible to determine which sample each read 
derives from: MIDs partly account for 454 NGS high throughput. These 
oligonucleotides (10-11 nucleotides long) were added between the sequencing key 
and the template specific primers of both forward and reverse primers.  
The forward and reverse BRAF exon 15 specific primers are 21 nucleotides long 
and situated at the 3-prime end of the oligonucleotides previously described 
(Table 3.10). 
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Figure 3.9. 454 Next-Generation Sequencing fusion primers. 
 
Gene Forward Primer Reverse Primer 
BRAF exon 15 CGTATCGCCTCCCTCGCGCCA  CTATGCGCCTTGCCAGCCCGC  
 
Table 3.10. 454 Next-generation BRAF exon 15 specific primers. 
 
3.4.2 Amplicon library preparation 
PCR conditions 
PCR was performed using a high fidelity hot-start protocol for amplicon 
generation in order to avoid amplification derived variations in the sequence and 
non-specifical elongation at low temperatures (FastStart High Fidelity PCR 
System, Roche). 
FastStart High Fidelity PCR System kit contains an Enzyme Blend (5 U/µl) 
consisting of a FastStart Taq DNA Polymerase with heat-labile blocking groups 
on amino acid residues and a chemically modified proofreading protein without 
polymerase activity both inactive below 75°C.  
For a final 25 μl reaction volume, the following reaction mix was added to each 
well: 0.2 mM dNTP mix (Roche), 1X FastStart High Fidelity Reaction Buffer 
(with 1.8 mM MgCl2), 1 mM MgCl2 Solution, 1.25 U of FastStart High Fidelity 
Enzyme Blend, 6.25 pmol of both forward and reverse primers, 15-40 ng of 
genomic DNA from FFPE tissues and molecular biology grade water 
(UltraPure™ DNase/RNase-Free Distilled Water, Gibco) to final volume. Each 
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reaction was covered with mineral oil (for molecular biology, light oil; Sigma-
Aldrich). 
PCR was performed in a thermal cycler using the conditions summarized in Table 
3.11: 
Step Temperature Time No. of cycles 
Initial denaturation/ Enzyme activation 95°C 2ʹ 1 
Denaturation 95°C 30ʹʹ 37 
Annealing 60°C 30ʹʹ 37 
Extension 72°C 1ʹ 37 
Final extension 72°C 7ʹ 1 
 
Table 3.11. PCR steps for 454 next-generation sequencing amplicon library preparation 
 
PCR products were run on a 2.5% agarose gel stained with GelStar stain (Lonza 
Bioscience) to screen them for the presence of the specific amplified DNA 
sequences (165 bp) and exclude a high presence of fusion primer dimers.  
 
Library purification 
The library preparation method of the 454 Sequencing System requires the PCR 
amplicon purification using a solid-phase paramagnetic bead purification system 
(Agencourt AMPure XP PCR Purification, Beckman Coulter).  
This procedure delivers DNA without contaminant carryover such as salt, 
unincorporated dNTPs, enzymes and small molecular species such as free 
Adaptors and Adaptor dimers. 
Briefly, in a well 20 μl of PCR products, 25 μl of molecular biology grade water 
(UltraPure™ DNase/RNase-Free Distilled Water, Gibco) and 65 μl of 
paramagnetic beads were mixed and incubated for 10 minutes at room 
temperature in order to allow the binding of PCR amplicons to the beads 
(Fig.3.12, step 1-2), then, after an incubation of the previous mixture on the 
magnet (Agencourt SPRIPlate 96 Super Magnet Plate) for 5 minutes at room 
temperature, the separation of PCR amplicons bound to magnetic beads from 
contaminants was obtained by supernatant discard (Fig.3.12, step 3). After 
washing twice PCR amplicons with 70% ethanol (Fig.3.12, step 4), elution of 
purified PCR amplicons from the magnetic particles (Fig.3.12, step 5) was 
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performed using 20 μl of 1x TE Buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 
Sigma-Aldrich). The purified PCR products were transferred away from the beads 
into a new plate (Fig.3.12, step 6) and were stable at 4° C until seven days.  
It is important to remove any free and dimerized Adaptors from the library before 
performing an emPCR amplification because they can compete against amplicons 
for binding to the Capture Beads during the preparation of the emPCR 
amplification reaction, the short size of dimers makes them good templates for 
amplification in the emPCR amplification reaction, and they would also be 
included in the quantification of the amplicons causing them to represent a sizable 
fraction of the final reads. 
 
Figure 3.12. Library purification process overview. 
 
The amplicons are quantitated separately and then pooled for emPCR 
amplification and sequencing, in equimolar representation. 
 
Library quantitation 
Post-cleanup of PCR products, the amplicons were fluorometrically quantitated 
using the Quant-iT PicoGreen
®
 dsDNA quantitation Assay Kit (Invitrogen) and 
measured with the QuantiFluor
®
-ST Fluorometer. 
Quantitation and pooling accuracy are very important in order to ensure that each 
amplicon is adequately represented in the sequencing Run. 
An eight point standard curve was prepared according to the manufacturer’s 
instructions performing serial dilution of the DNA standard provided in 1x TE 
Buffer with the amounts of DNA per standard well listed in Table 3.13. The 
coefficient of determination value of the standard curve accepted to obtain 
accurate quantitation of samples was R
2 
>0.98. 
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Standards DNA concentration 
1 100 ng/well 
2 50 ng/well 
3 25 ng/well 
4 12.5 ng/well 
5 8.25 ng/well 
6 3.13 ng/well 
7 1.56 ng/well 
8 0 ng/well 
 
Table 3.13. DNA concentrations of the standard curve points.  
 
The PicoGreen
®
 dye was diluted to 1:200 with 1x TE and 100 μl of the diluted 
dye were mixed with 100 μl of both standard dilutions and 1:100 diluted samples 
before the quantitation of the standard curve points and the samples. 
 
Amplicon dilution and pooling 
The concentration of unknown samples was calculated in ng/μl from fluorescence 
signals by interpolation from the standard curve in an Excel-file that contained 
also the amplicon lengths allowing the concentrations of amplicons to be 
converted from ng/μl to molecules/μl using the following formula: 
 
Then, single amplicons were diluted with 1x TE Buffer to 1x10
9 
molecules/μl and 
pooled by mixing an equal volume (for example, 10 μl) of each amplicon. 
The amplicon pool was diluted to 1x10
7 
molecules/μl by adding 10 μl of the 
amplicon pool to 990 μl molecular biology grade water. This is a stop step: the 
1x10
9 
molecules/μl single amplicon dilutions, the pool and the 1x10
7 
molecules/μl 
dilution can be stored at -20°C.  
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3.4.3 Emulsion PCR (emPCR) 
Emulsion PCR (emPCR) is a PCR amplification within aqueous droplets that 
function as amplification microreactors in an oil-aqueous emulsion allowing 
multiple simultaneous PCR reactions to be performed. Each droplet contains all 
reagents necessary for PCR reaction and can encapsulate an individual bead 
annealed to a single DNA fragment. This annealing occurs because sepharose 
beads carry immobilized primers complementary to the library A or B adaptors 
respectively: thus the amplification of the DNA fragment can be performed both 
in forward and in reverse (Lib-A method). During the amplification the 
immobilized primers are elongated by the DNA polymerase so the PCR products 
remain attached to the bead surface. After the emulsion PCR amplification, each 
droplet contains a bead carrying several thousand clones of the same template 
sequence captured by the bead (Fig. 3.14). 
 
Figure 3.14. Emulsion PCR (emPCR) process. 
 
First of all, the pool was further diluted in order to achieve 1.2 DNA molecules 
per DNA Capture Bead, whose total number is 5x10
6
, using the following 
equation: 
 
 
 
Considering the scarce volume calculated (0.6 μl), a 1:20 dilution of the pool was 
prepared in molecular biology grade water (UltraPure™ DNase/RNase-Free 
Distilled Water, Gibco)such that the volume to be added is higher (12 μl). 
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This 1:1 proportion of DNA fragments and beads guarantees a low number of 
both the beads carrying no DNA fragments (empty emPCR beads) and the ones 
with more than one DNA amplicon (mixed emPCR beads) due to stochastic 
variations during the emulsion PCR process. Thus, library quantitation is a critical 
step for 454 next-generation sequencing to avoid high presence of beads that can’t 
produce readable sequences. 
Two identical mixes, except for primers, were prepared in separated tubes as 
follows: 205 μl of molecular biology grade water (UltraPure™ DNase/RNase-
Free Distilled Water, Gibco), 260 μl of Additive, 135 μl of Amp Mix, 35 μl of 
Enzyme Mix, 1 μl of PPiase and 40 μl of either primer A or B. 
The volume of the Amplicon DNA library (12 μl) was added to both the tubes of 
washed Capture Beads A and Capture Beads B, then 600 μl of previously 
prepared mix containing either primer A or B were mixed with Capture Beads A 
or B respectively.  
The emulsion was prepared pouring first the emulsion oil into the IKA Ultra 
Turrax stirring tube with 2 ml of 1x Mock Mix and shaking them at 4000 rpm for 
5 minutes and then adding the entire volume contained both in the tube of 
captured library B and A mixing at 2000 rpm for 5 minutes after each addition. 
The emulsion was dispensed in a 96-well plate aliquoting 100 μl in each well and 
PCR was performed in a thermocycler with the heated lid turned on using the 
amplification program summarized in Table 3.15. The emPCR preparation 
requires about two hours to be performed and the program takes about 6 hours to 
complete.  
 
Step Temperature Time No. of cycles 
Initial denaturation 94°C 4ʹ 1 
Denaturation 94°C 30ʹʹ 50 
Annealing 56°C 4ʹ30ʹʹ 50 
Extension 68°C 30ʹʹ 50 
Final hold 10°C up to 16 h 1 
 
Table 3.15. Emulsion PCR (emPCR) steps. 
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3.4.4 Recovery and enrichment processes 
The emulsion was aspirated from the plate through a transpette into a 50 ml 
conical tube using a vacuum source: this Emulsion Breaking Apparatus is 
provided in the GS Junior Titanium Oil and Breaking Kit (Fig. 3.16)  
 
Figure 3.16. Vacuum-assisted Emulsion Breaking Apparatus. 
 
The emulsion was broken and beads were washed using isopropanol and absolute 
ethanol followed by centrifugations.  
The beads carrying amplified DNA are separated from empty beads by an 
enrichment process, whereas the ones with more than one DNA amplicon (mixed 
beads) are discarded after sequencing Run during data processing. 
The enrichment was performed according to manufacturer’s instructions. 
Briefly, a Melt Solution containing NaOH was incubated with the washed beads: 
it removes the non-immobilized complementary strands from the beads thus PCR 
amplicons become single stranded. The Capture Beads carrying single stranded 
PCR amplicons were then incubated with biotinylated Enrich Primer A and 
Enrich Primer B: these primers anneal to DNA fragments on Capture beads. The 
Enrichment Beads, streptavidin-coated magnetic beads, capture all the beads 
carrying DNA fragments by the biotinylated Enrich Primers. A Magnetic Particle 
Concentrator (MPC) allows the DNA positive beads to be separated from empty 
beads that are discarded. Finally, the beads carrying DNA were recovered by 
Enrichment Primers denaturation using the Melt Solution, the Sequencing Primers 
were added and the beads were counted.  
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In this study, bidirectional sequencing was performed because it provides higher 
sequencing accuracy. Therefore, two kinds of primers, “Primer A” and “Primer 
B”, were used for target amplicon sequencing from either end. In order to 
consider a variant found as a valid mutation the independent confirmation of 
sequence by both forward and reverse reads was required because it reduces 
sequencing errors (see the section titled “Assessment of variants”). 
The Seq Primer A e B (15 μl each) anneal to the bead bound to hybridized to 
single-stranded PCR amplicons that serve as a template and their excess is 
removed through a series of washes. 
The recovery and enrichment processes require about 2.5 hours to be carried out. 
In order to evaluate the amount of enriched beads, the GS Junior Bead Counter 
was used: the recommended input bead number for a GS Junior sequencing Run is 
500,000 enriched beads (5% enrichment) that corresponds to the top of the bead 
pellet at the level of the bottom edge of the window. The upper line corresponds 
to 2 million beads (20% enrichment) (Figure 3.17). 
 
 
 
Figure 3.17. Bead counting and enrichment percentage. 
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3.4.5 Parallel pyrosequencing  
The GS Junior Sequencing procedure consists of four steps: after the instrument’s 
fluidics washing with Pre-wash Buffer, the PicoTiterPlate (PTP), a fiber-optic 
slide, was placed into a flow chamber, the Bead Deposition Device (BDD), for the 
following bead layers deposition (Fig 3.18), then the instrument was primed with 
reagents and buffers and the sequencing Run was performed. 
Before the bead layers deposition, 350 μl of BB2 Buffer, containing the Apyrase 
enzyme, were loaded onto the plate placed into the chamber. 
The PicoTiterPlate (PTP) was then filled with DNA Beads, Packing Beads, 
Enzyme Beads and PPiase beads in separate layers by injection of bead 
suspensions followed by centrifugation in the order specified in Figure 3.18. 
These smaller beads surround the template beads and permit the NGS chemistry. 
 
 
Figure 3.18. Bead Deposition Device (BDD) and procedure. 
 
The DNA-carrying beads were deposited into the wells of the PicoTiterPlate 
(PTP), such that no more than a single bead carrying clonally amplified DNA is 
deposited into an individual well. In the Titanium version, the inner side of wells 
is titanium-coated in order to increase read length and reduce crosstalk between 
adjacent wells. Fundamental reagents for NGS chemistry are contained in the 
DNA Bead suspension (Polymerase, Polymerase Cofactor, BB2 Buffer and 
Packing Beads). The sequencing Run preparation requires about two hours to be 
performed. 
The Roche 454 sequencing system implements pyrosequencing technology, 
method that relies on the detection of inorganic pyrophosphate release during 
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nucleotide incorporation converting it into proportional bioluminescence using 
enzymatic reactions [250, 269].  
Instead of using dideoxynucleotides to terminate the chain amplification, in the 
pyrosequencing method the addition of dNTPs is performed sequentially in a 
fixed order and in limiting amounts: therefore DNA polymerase extends the 
primer and pauses until the addition of the next complementary dNTP. The 
incorporation of the complementary dNTPs onto the template causes a 
stoichiometrical release of pyrophosphate (PPi) that triggers the sequential 
reactions of sulfurylase and luciferase, the enzymes attached to the enzyme beads. 
ATP sulfurylase converts PPi to ATP in the presence of adenosine 5' 
phosphosulfate (APS). This ATP drives the luciferase-catalyzed conversion of 
luciferin to oxyluciferin that generates visible light in amounts that are 
proportional to ATP and, therefore, to the number of nucleotides incorporated 
(Fig. 3.19). Since ATP is also substrate for luciferase reaction, during nucleotide 
flow an ATP analogue, able to match thymine but not to be substrate for 
luciferase enzyme, is used. The unmatched nucleotides and ATP are converted to 
nucleoside monophosphate by the apyrase before the restart of the reaction with 
the next nucleotide. Another enzyme, pyrophosphatase (also referred to as PPiase) 
is flowed at the end of each nucleotide flow cycle to degrade any excess PPi. 
Hence, these enzymes avoid aspecific reactions. The sequential flow of the four 
dNTPs is performed 200 times during a Run which requires about ten hours to be 
performed. 
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Figure 3.19. 454 Next-Generation Sequencing chemistry [269]. 
 
3.4.6 454 Sequencing System data handling  
Data handling in the 454 Sequencing System consists of three phases: data 
acquisition, data processing and data analysis.  
 
Data acquisition 
During the data acquisition phase, carried out by the GS Junior Sequencer 
software, a set of raw digital images captured by the camera are recorded .Each 
image represents the surface of the PicoTiterPlate device during one nucleotide 
flow. If the DNA fragments immobilized on a bead located in a given well are 
extended during a nucleotide flow, light is emitted from the PTP well and detected 
by a high-resolution charge-coupled device (CCD) camera directly attached to the 
lower side of the PicoTiterPlate and captured on the image (Fig. 3.20). 
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Data processing 
During the data processing phase, controlled by the GS Run Processor 
application, raw image data are converted into base-called results. Data processing 
requires two hours to be carried out and consists of two steps, image processing 
and signal processing (Fig. 3.20).  
 
Figure 3.20. Data acquisition and processing. 
 
The software first measures the amount of light emitted in each active well during 
each flow (image processing step) then it performs a series of automatic data 
correction steps that compensate for optical effects and chemical inefficiencies 
and segregates low quality reads and, finally converts signal intensities of high 
quality reads into a series of peaks called a flowgram (signal processing step). The 
height and the order of the peaks reveal the DNA sequence (Fig. 3.21). Therefore, 
GS RunProcessor produces a series of files including SFF (standard flowgram 
format) files containing the basecalled sequences and per-base quality scores. 
 
 
Figure 3.21. The flowgram. 
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Data analysis 
During the data analysis phase, a software uses as input the reads and flowgrams 
output in SFF format obtained through data processing. 
The GS Amplicon Variant Analyzer (AVA) software was used: it assigns each 
read to the proper amplicon using MID information, aligns amplicon reads to a 
reference sequence and thus identifies differences between the reads and the 
reference sequence providing also a quantitation of known or novel sequence 
variants. AVA trims the PCR primer sequences from the reads: the PCR specific 
primer part in the sequencing reads is by definition equal to the genomic reference 
sequence and thus independent of the individual sample that is sequenced. This 
software displays the variant positions and their frequency both with histograms 
and with a multiple alignment of forward and reverse reads to the reference (Fig. 
3.22). 454 Sequencing system produces hundreds to thousands of clonal reads for 
each amplicon that results in unambiguous haplotyping intuitively displayed by 
AVA and in confident calling of low-frequency variations.  
 
 
Figure 3.22. BRAFwt (A) and BRAFV600E (B) samples by 454 NGS. 
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Assessment of variants 
The variations observed in the reads were carefully evaluated before considering 
them to be true variants in BRAF exon 15. 
In this study a cutoff of 1% of total reads was set to consider BRAF exon 15 
carrying the variant in a sample with a number of at least 10 mutated reads to 
believe that the variant is not an artifact. 
Since C→T/G→A or A→G/T→C transitions can be artificially incorporated into 
DNA extracted from microdissected sections of samples fixed in formalin, 10 
normal tissues from patients without neoplasms were also screened for the 
presence of BRAF exon 15 mutations in order to further validate uncommon 
mutations [279, 280]. 
Moreover, in order to reduce the risk of false positives, some features of the 
variants found in the reads were considered: the bidirectional support, the 
proximity of homopolymers, the noise level and the coverage. 
Variants found in either forward or reverse reads, were excluded whereas the 
confidence in validity was strengthened if the frequency of a variant was similar 
in both directions. This corroborating evidence is particular important for variants 
found in close proximity of the trailing edge of a read that are considered less 
believable because sequencing quality can begin to drop off at the end of an 
amplicon read. 
Pyrosequencing is quite imprecise in the sequencing of homopolymeric regions 
exceeding the length of a few nucleotides (longer than 6 bases): the presence of a 
homopolymer of the same nucleotide in close proximity upstream or downstream 
of the one impacted by the variant, could have caused an undercall or overcall due 
to known sequencing artifacts called carryforward and incomplete extension. 
Hence, also these variants were excluded. 
Moreover, only the low frequency variants convincingly above the noise level, 
which is the presence of many low level frequency variations in the plot, and with 
high depth of coverage were considered. Synonymous variants were not reported. 
 
After assessment of validity, an interrogation of the Catalogue of Somatic 
Mutations in Cancer database (COSMIC) and a literature search with PubMed 
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was performed in order to know if mutations observed were previously known in 
PTC, in other cancers or unknown [154].  
Moreover, the tool PolyPhen-2 (Polymorphism Phenotyping v2) was used to 
predict possible impact of a given non-synonymous variant on the structure and 
function of the BRAF protein. This tool, through an in silico prediction algorithm 
considering sequence-based, structural and phylogenetic information, associates a 
score to each mutation and predicts that it will be benign (0-0.2), possibly 
damaging (0.2-0.85), or probably damaging (0.85-1) [281].  
 
3.5 Analysis of BRAF clonality: evaluation of mutated 
neoplastic cells proportion 
Since the analysis of genetic heterogeneity in tumors can be deeply biased by 
“contamination” with non-tumoral cells, two pathologists estimated the amount of 
neoplastic cells in each tumor sample and the percentage of mutated cells obtained 
by ASLNAqPCR or 454 NGS was normalized on this proportion thus obtaining a 
better appraisal of mutated neoplastic cells proportion. 
Assuming BRAF
V600E
 heterozygous, the percentage of mutated cells obtained by 
ASLNAqPCR corresponds to the double of the mutated allele percentage. 
The following formula (where R is the ratio of BRAF mutated versus wild type 
allele and X is the estimated percentage of neoplastic cells) was used for 
ASLNAqPCR method: 
 
% mutated neoplastic cells=(R/X)*100 
 
Similarly, the percentage of mutated cells obtained by 454 NGS was normalized 
on the one of neoplastic cells using the following formula (where MR is the 
percentage of mutated reads by 454 NGS and X is the estimated percentage of 
neoplastic cells): 
 
% mutated neoplastic cells=[(MR*2/X)]*100 
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Statistical analysis was performed using GraphPad Prism 5.0 tool: results with a 
p-value < 0.05 were considered to be statistically significant. 
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CHAPTER 4 
RESULTS 
 
4.1 1 Aim 1 - Clonality of BRAF
V600E
 mutation in PTC  
4.1.1 Analysis of PTCs for BRAF
V600E 
by ASLNAqPCR 
For the first project, 155 consecutive FFPE thyroid specimens of PTCs were 
analyzed. These samples were genotyped for the presence of BRAF
V600E
 mutation 
using the ASLNAqPCR semi-quantitative technique, which not only detects 
BRAF
V600E
 but also permits to assess the percentage of BRAF
V600E
 mutated allele.  
Eighty five out of 155 samples (54.8%), corresponding to 78 patients, aged from 
25 to 79 years (mean 53 years) were mutated for BRAF
V600E
. The frequency here 
observed is in line with that reported in literature for BRAF
V600E
 mutation in PTCs 
[93].  
BRAF
V600E
 mutated PTCs were further subdivided according to size and 
histological diagnosis in: papillary microcarcinoma (mPTC), PTC-classic (PTC 
Cl), PTC-follicular variant (PTC FV) and PTC-tall cell (PTC TC) (Fig. 4.1). 
 
Figure 4.1. Distribution of analyzed PTC samples. PTC, papillary thyroid carcinoma;  mPTC, papillary 
microcarcinoma; PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular variant; WT, wild-
type PTC. 
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As discussed in section 3.5, the analysis of genetic tumoral heterogeneity can be 
deeply biased by “contamination” due to non-tumoral cell DNA (stromal, 
endothelial and inflammatory cells). For this reason, the analyzed areas were 
estimated by two pathologists evaluating the amount and the proportion of 
neoplastic cells within each sample. On the assumption that the BRAF
V600E
 
mutation is heterozygous in PTC cells, the percentage of mutated cells obtained 
by ASLNAqPCR corresponds to the double of the mutated allele percentage. In 
Figure 4.2 three representative BRAF
V600E
 mutated tumors (PTC cases 67, 69 and 
65) where the mutation is present in virtually all neoplastic cells (Fig. 4.2 A) and 
those of 3 representative BRAF
V600E
 mutated tumors (PTC cases 24, 7 and 6) 
where the mutation is present in a minority of neoplastic cells (Fig. 4.2 B) are 
shown.  
 
 
Figure 4.2. PTCs showing clonal (A) or subclonal (B) distribution of BRAFV600E mutation (H&E). The 
boxes show the percentage of neoplastic cells in the tumor, the percentage of BRAFV600E mutated allele 
obtained by ASLNAqPCR, and the percentage of BRAFV600E mutated cells after normalization to the 
estimated proportion of neoplastic cells within the tumor. 
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Of the 85 mutated PTCs, 51 were PTC (sized 11 to 55 mm) and 34 were 
diagnosed as papillary microcarcinoma (mPTC) (sized 3 to 10 mm) further 
subdivided in histological variants whose features are shown in Table 4.3 and 
Table 4.4 respectively. The calculated ratios (R = 2
-(CtV600E-CtWT)
) were between 
0.01 and 0.82 (mean value 0.32, median value 0.29) and, after normalization to 
the proportion of neoplastic cells within the tumor, the percentage of neoplastic 
cells carrying the BRAF
V600E
 mutation ranged from 4% to 107.1% (mean value 
67.5% median value 65.0%).  
PTC 
histology 
Range of 
tumor size 
(mm) 
BRAF
V600E  
PTCs 
Range of 
ratios (R) 
Range of 
neoplastic cells 
(X) 
Range of BRAF
V600E 
neoplastic cells 
(R/X)*100 
PTC Cl 11-55 29 0.09-0.62 28%-80% 19.2%-104.8% 
PTC TC 11-42 17 0.08-0.82 25%-80% 32%-107.1% 
PTC FV 11-16 5 0.06-0.7 15%-70% 40%-100% 
Total 11-55 51 0.06-0.82 15%-80% 19.2%-107.1% 
 
Table 4.3. Features of histological variants of PTCs BRAFV600E mutated analyzed by ASLNAqPCR. 
PTC, papillary thyroid carcinoma; PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular 
variant. 
In the 34 BRAF
V600E
 mutated mPTC (equal to or less than 1 cm diameter) of the 
85 BRAF mutated samples the percentage of mutated neoplastic cells, after 
normalization to the proportion of neoplastic cells within the tumor, ranged from 
4% to 106% (mean 63.8%, median 65.6%). 
mPTC (≤1 cm) 
histology 
Range of 
tumor size 
(mm) 
BRAF
V600E  
mPTCs 
Range of 
ratios (R) 
Range of 
neoplastic 
cells (X) 
Range of 
BRAF
V600E 
neoplastic cells 
(R/X)*100 
PTC Cl 3-10 16 0.03-0.8 3%- 80% 18.8%-100% 
PTC TC 3- 10 8 0.06-0.55 6%-80% 62.5%- 106% 
PTC FV 3-10 10 0.01-0.49 15%- 70% 4-100% 
Total 3-10 34 0.01-0.8 3%- 80% 4-106% 
 
Table 4.4. Features of histological variants of mPTCs BRAFV600E mutated analyzed by ASLNAqPCR. 
PTC, papillary thyroid carcinoma; mPTC, papillary thyroid microcarcinoma; PTC Cl, PTC-classic; PTC TC, 
PTC-tall cell; PTC FV, PTC-follicular variant. 
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4.1.2 Distribution of BRAF
V600E
 mutated neoplastic cells in PTCs 
and mPTCs by ASLNAqPCR 
Three groups of tumors could be identified in BRAF
V600E
 PTCs (Fig.4.5 A) and in 
BRAF
V600E
 mPTCs (Fig.4.5 B): 1) tumors with less than 30% of BRAF
V600E
 
mutated neoplastic cells; 2) tumors with a percentage of mutated neoplastic cells 
between 30 and 80%; 3) tumors with more than 80% mutated neoplastic cells. In 
many PTC samples the mutation was detected in a large neoplastic cell sub-
population: 37 of 85 tumors (43.5%) harbored the BRAF
V600E
 in more than 80% 
mutated neoplastic cells. In 39 of 85 (45.9%) BRAF
V600E
 mutated PTCs, the 
percentage of mutated neoplastic cells was between 30 and 80%. In 9 cases 
(10.6%) the percentage of BRAF
V600E
 mutated neoplastic cells was below 30% 
and in a single case was less than 10%. The distribution of mutated neoplastic 
cells in mPTCs was virtually identical to that observed for PTC samples > 1cm 
(Fig. 4.5 B). 
 
Figure 4.5. Percentage of mutated neoplastic cells in all PTCs (A) and in mPTCs (B). In x axe the 
percentage of mutated neoplastic cells is indicated. Dotted lines indicate 30% and solid lines indicate 80% of 
BRAFV600E mutated neoplastic cells, respectively. 
Before normalization according to neoplastic cells, only one sample displayed a 
percentage of mutated neoplastic cells > of 80%, while the rest of the samples 
showed a lower percentage of neoplastic cells with BRAF
V600E
 mutation (Fig. 4.6 
A). The percentage of mutated neoplastic cells, before normalization to the 
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estimated proportion of neoplastic cells within the tumor, ranged from 1% to 82% 
(mean 32%, median 29%). 
The non normalized results are similar to those previously reported in PTCs based 
on pyrosequencing analysis of the BRAF
V600E
 mutation [248, 266]. 
 
Figure 4.6. Percentage of mutated neoplastic cells in all PTCs before (A) and after normalization (B). In 
y axe the percentage of mutated neoplastic cells is indicated. Black bars, tumors > 1 cm; white bars tumors ≤ 
1 cm (mPTC). 
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4.1.3 Analysis of PTCs for BRAF
V600E 
by 454 NGS  
To strengthen the validity of the analysis, 30 of the 85 BRAF
V600E
 mutated PTCs 
were also analyzed using a second semi-quantitative technique, a 454 NGS 
targeted re-sequencing (Fig. 4.7). The presence of the mutation was confirmed in 
all 30 cases and no mutations other than the V600E were identified. The number 
of reads ranged from 160 to 1859 (average of 876 and a median of 882 reads).  
 
 
Figure 4.7. Percentage of mutated neoplastic cells in 30 BRAFV600E mutated samples using 
ASLNAqPCR (left) or 454 NGS (right). 
The number of mutated neoplastic cells was similar with both ASLNAqPCR 
(mean 67.4% and median 65.0%) and 454 NGS (mean 72.3% and median 83.0%) 
corresponding to approximately 35-40% of BRAF
V600E
 mutated alleles in each 
PTC sample. The paired t-test showed no statistical difference between the results 
of BRAF mutational analysis performed by ASLNAqPCR and NGS (p=0.1064, 
Wilcoxon signed rank test) (Fig. 4.8). 
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Figure 4.8. Box plots showing the percentage of mutated neoplastic cells in 30 samples using 
ASLNAqPCR and 454 NGS. ASLNA, Allele Specific Locked Nucleic Acid quantitative PCR; NGS, Next-
Generation Sequencing. 
Regression analysis showed a strong correlation between the percentage of 
mutated neoplastic cells detected by ASLNAqPCR and the value obtained by 
NGS (r
2
= 0.6152, p=0.0002, Spearman test) (Fig. 4.9).  
 
Figure 4.9. Correlation between the percentage of mutated neoplastic cells in 30 samples using 
ASLNAqPCR and 454 NGS. 
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4.1.4 Correlation of BRAF
V600E
 mutated alleles and clinico-
pathological features of PTCs 
The distribution of PTC subtypes in the three BRAF
V600E
 groups observed was 
analyzed and is described in Table 4.10. 
PTC 
histology 
Mutated neoplastic cells  
within the tumor Total 
<30% 30%-80% >80% 
PTC Cl 2 17 10 29 
PTC TC 0 6 11 17 
PTC FV 0 3 2 5 
mPTC 7 13 14 34 
Total 9 39 37 85 
Table 4.10. Distribution of histological variants of PTCs in the three BRAFV600E groups. PTC, papillary 
thyroid carcinoma; PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular variant; mPTC, 
papillary thyroid microcarcinoma. 
The majority of classic PTCs (17/29 cases), belonged to the 30-80% BRAF
V600E
 
group (Fisher’s exact test p=0.1107). The majority of tall cell PTCs (11/17 cases) 
belonged to the >80% BRAF
V600E
 group (Fisher’s exact test p=0.0596). The 
mPTCs were statistically associated with the tumor group featuring less than 30% 
BRAF
V600E
 mutated cells (chi-squared test p=0.0440; Fisher’s exact test p=0.0238, 
<30% vs. 30-80% BRAF
V600E
 mutated cells; p=0.0582, <30% vs. >80% 
BRAF
V600E
 mutated cells; p=1.000, 30-80% vs. >80% BRAF
V600E
 mutated cells). 
The percentage of BRAF
V600E
 mutated cells was correlated with tumor size, 
patients’ age, tumor stage and lymph node metastases (LNM): there wasn’t any 
statistically significant correlation between the percentage of mutated neoplastic 
cells and the size of the tumor (Fig. 4.11 A), age of the patients (Fig. 4.11 B) and 
stage (Fig. 4.11 C).  
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Figure 4.11. Correlation between the percentage of mutated neoplastic cells and the size of the tumor 
(A), age of the patients (B) and stage (C). Statistical correlation (Spearman test) between the percentage of 
BRAFV600E mutated cells within the tumor and size (p=0.1121), age (p=0.4891) and stage (p=0.3089). 
Moreover, there was no statistical correlation between the percentage of mutated 
neoplastic cells and the presence of lymph nodal metastasis (Fig. 4.12 A, B). 
 
Figure 4.12. Histograms (A) and box plots (B) showing the distribution of mutated neoplastic cells in 
tumors without (N0) or with lymph nodal metastasis (N1). Statistical correlation (Mann-Whitney test) 
between the percentage of mutated neoplastic cells and the presence of lymph nodal metastasis (p=0.7172). 
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4.2 Aim 2 - Screening of BRAF mutations in exon 15 in 
histologically benign thyroid tissue 
Seventy-five histologically benign FFPE thyroid specimens from 20 cases with 
BRAF
V600E
 mutated PTCs aged from 30 to 79 years (mean 47 years) and 23 from 
9 cases with BRAF
wt
 PTCs aged from 29 to 70 years (mean 43 years) (unpaired t-
test, p=0.2245) were analyzed by 454 Next-Generation Sequencing (NGS) semi-
quantitative technique for investigating the possible presence of BRAF
V600E
 
mutation and uncommon ones in exon 15. Ten samples with histologically normal 
thyroid parenchyma were analyzed by 454 NGS. 
Each target sequence was analyzed from 123 to 4,345 reads per target (mean 
1,358.8) with mutations ranging from 1% to 30%.  
BRAF
V600E 
mutation was confirmed by 454 NGS in all 20 BRAF
V600E 
PTCs 
previously analyzed using other techniques (Sanger sequencing or ASLNAqPCR). 
The histologically benign thyroid specimens are subdivided according to 
histological features in: “atypical focus”, hyperplasia (HYP), follicular adenoma 
(FA), oncocytic follicular adenoma, psammoma body (PB) and normal tissue. 
Two out of 23 samples (8.7%) from the group with BRAF
wt
 PTCs showed the 
presence of 3 BRAF
 
mutations. The proportion of BRAF mutations observed in 
histologically benign FFPE thyroid specimens from the group with BRAFwt PTCs 
is shown in Table 4.13. 
Histology 
BRAF
mut 
histologically 
benign samples 
BRAF
wt 
histologically 
benign samples 
Total 
Atypical focus 1  (20%) 4  (80%) 5 
HYP 0 3  (100%) 3 
FA 1  (33.3%) 2  (66.7%) 3 
PB 0 3  (100%) 3 
Normal 0 9  (100%) 9 
Total 2  (8.7%) 21  (91.3%) 23 
 
Table 4.13. Detection of BRAF mutations in histologically benign FFPE thyroid specimens from the 
group with BRAFwt PTCs. HYP, hyperplasia; FA, follicular adenoma; PB, psammoma body. 
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Twenty one out of 75 samples (28%) from the group with BRAF
V600E
 mutated 
PTCs showed the presence of 21 BRAF
 
mutations in 14 codons. Four out 21 
samples (19%) carried the BRAF
V600E 
mutation. The proportion of BRAF 
mutations observed in histologically benign areas of BRAF
V600E
 mutated PTCs is 
shown in Table 4.14. Mutations were observed in 6 out of 32 atypical foci 
(18.8%), 4 out of 13 hyperplasias (30.8%), 1 out of 2 (50%) follicular adenomas, 
3 psammoma bodies (100%) and 7 out of 24 (29.2%) normal areas. 
Histology 
BRAF
mut 
histologically 
benign samples 
BRAF
wt 
histologically 
benign samples 
Total 
Atypical focus 
a
 6  (18.8%) 25  (78.1%) 32 
HYP 4  (30.8%) 9  (69.2%) 13 
FA 0 1  (100%) 1 
Oncocytic FA 1  (50%) 1  (50%) 2 
PB 3  (100%) 0 3 
Normal 
a
 7  (29.2%) 16  (66.7%) 24 
Total 21  (28%) 52  (69.3%) 75 
 
Table 4.14. Detection of BRAF mutations in histologically benign FFPE thyroid specimens from the 
group with BRAFV600E mutated PTCs. HYP, hyperplasia; FA, follicular adenoma; PB, psammoma body. 
a 
In one out of 32 atypical foci (3.1%) and in one out of 24 (4.2%) normal areas DNA analysis was 
unsuccessful due to acid nucleic degradation (2/75 samples, 2.7%). 
 
There was no statistically significant difference in the occurrence of BRAF 
mutations between the group of histologically benign thyroid specimens with 
BRAF
V600E
 and the group of specimens with BRAF
wt 
PTCs (p=0.0546, Fisher’s 
exact test). Also the differences in the occurrence of BRAF mutations between the 
atypical foci (p=1.0000), hyperplasias (p=0.5286), follicular adenomas 
(p=1.0000), psammoma bodies (p=0.1000) and normal tissues (p=0.1492) from 
the group with BRAF
V600E
 PTCs and the ones from the group of specimens with 
BRAF
wt 
PTCs were not statistically significant (Fisher’s exact test). 
An interrogation of the Catalogue of Somatic Mutations in Cancer database 
(COSMIC) and a literature search with PubMed was performed in order to know 
if mutations observed were previously described in PTC, in other cancers or 
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unknown [154]. The mutations here found were all single nucleotide substitutions 
(no indels were observed) and had been all previously described. The mutations 
that met the criteria defined in section 3.4.6 for the assessment of mutational calls 
were all missense mutations except for one nonsense mutation. In the 10 
histologically normal thyroid samples analyzed by 454 NGS no mutations were 
found. Moreover, no mutations other than the V600E were identified in 
BRAF
V600E
 PTCs samples except for one case where the same mutation, T599I, 
was found at low frequency both in PTC (2.6% of 971 reads) and normal tissue 
(3% of 923 reads) from the same thyroid lobe (case No. 9, Table 4.23).  
The tool PolyPhen-2 (Polymorphism Phenotyping v2) was used to predict 
possible impact of a given non-synonymous variant on the structure and function 
of the BRAF protein. This tool, through an in silico prediction algorithm, 
associates a score to each mutation and predicts if it could be benign (B) if the 
score is in the range 0-0.2, possibly damaging if the score is in the range 0.2-0.85 
or probably damaging if it is in the range 0.85-1 (PD) [281].  
BRAF
V600E
 and BRAF
K601E
 are here defined “usual” mutations according to the 
percentages reported in literature. BRAF
V600E
 is the most frequent genetic 
alteration in papillary thyroid cancer: it accounts for about 95% of BRAF mutation 
in PTC (40-45% of all PTC genetic alterations) [7, 135, 136]. BRAF
V600E
 is 
typically found in tumors with classic papillary (60%) and tall-cell histology 
(80%), and is rare in the follicular variant (10%) [93, 94]. By contrast, BRAF
K601E
 
is typically associated to the follicular variant of papillary carcinoma (7-10% of 
FV PTC) [96, 142, 144]. 
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4.2.1 Exon 15 BRAF
 
mutations in histologically benign thyroid of 
the BRAF
wt
 PTC group  
The BRAF
E586K 
and BRAF
V600E 
mutations were identified in the same focus of 
“atypical” cells from a patient with a BRAFwt PTC (case No. 24, Table 4.15). The 
evidence that the mutations are on different strands determined that they are on 
different alleles (Fig. 4.16). 
The BRAF
K601E
 mutation was found in one FA: the same mutation had been 
previously described in only in 2 FA [64, 141, 144]. According to PolyPhen-2 
score, all these mutations may affect protein function. In functional in vitro 
studies it was observed that BRAF
E586K
, BRAF
K601E
, as well as BRAF
V600E 
have all 
elevated kinase activity[126, 130, 134, 146].  
Protein 
change 
Histologic 
variant of 
related 
BRAFwt  
PTC 
Type of 
sample 
Median 
percentage 
of mutated 
allele (reads) 
In-silico prediction 
of effect on protein 
function 
(PolyPhen-2) 
References 
Possible 
kinase 
activity 
score Prediction 
E586K 
PTC FV 
Case No. 24 
Atypical 
focus 
5.5%  (659) 1 PD 
COSMIC:  
- melanoma  
- ovarian carcinoma  
High activity 
mutant 
(Wan P.T. et al., 
2004; Emuss et al., 
2005) 
V600E 15.2%  (798) 0.971 PD 
COSMIC:  
- thyroid carcinoma  
- others  
High activity 
mutant 
(Davies et al., 2002; 
Ikenoue T. et al., 
2003; Wan P.T. et 
al., 2004) 
K601E 
PTC Cl 
Case No. 28 
FA 21.1%  (123) 0.784 PD 
COSMIC: 
- PTC 
- FA 
- melanoma 
- benign melanocytic 
nevus 
- others 
 
Lupi C. et al., 2007: PTC FV 
Soares P. et al., 2003; Lima J. 
et al., 2003; Trovisco V. et 
al., 2005: FA 
High activity 
mutant 
(Ikenoue T. et al., 
2003; Wan P.T. et 
al., 2004) 
 
Table 4.15. Type of BRAF mutations in histologically benign FFPE thyroid specimens from the group 
with BRAFwt PTCs and their possible effects on protein function. PTC, papillary thyroid carcinoma; PTC 
Cl, PTC-classic; PTC FV, PTC-follicular variant; FA, follicular adenoma; PD, possibly or probably damaging 
mutation. 
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Figure 4.16. BRAFE586K and BRAFV600E mutations in an “atypical focus” from a patient with a BRAFwt 
PTC (case No. 24). BRAFE586K (blue box) and BRAFV600E (red box) are on different strands. 
 
4.2.2 “Usual” exon 15 BRAF mutations in histologically benign 
thyroid lesions of the BRAF
V600E
 mutated PTC group  
The screening of exon 15 BRAF
 
 mutations by 454 NGS in histologically benign 
thyroid of cases with BRAF
V600E
 PTCs showed the presence of BRAF
V600E 
 in one 
“atypical focus” of 32 (3.1%) and in all 3 psammoma bodies (PBs) found in this 
group of histologically benign specimens. Moreover, in a further case of “atypical 
focus” the presence of BRAFK601E mutation was detected (Table 4.17).  
Protein 
change 
Histologic variant 
of related PTC 
 
Type of sample 
Median percentage of 
mutated allele (reads) 
V600E 
PTC FV 
Case No. 3 
Atypical focus 
 
PB 
4.9% (1091) 
 
2.1% (949) 
PTC Cl 
Case No. 6 
PB 1.6% (1409) 
PTC FV 
Case No. 8 
PB 2.3% (980) 
K601E 
PTC Cl 
Case No. 6 
Atypical focus 4.5% (947) 
 
Table 4.17. “Usual” exon 15 BRAF mutations in histologically benign FFPE thyroid specimens from 
the group with BRAFV600E PTCs. PTC, papillary thyroid carcinoma; PTC Cl, PTC-classic; PTC FV, PTC-
follicular variant; PB, psammoma body. 
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4.2.3 Exon 15 BRAF
 
mutations in psammoma bodies (PBs) 
A total of 6 PBs were here analyzed, 3 from histologically benign thyroid of 
patients with BRAF
V600E
 PTCs and 3 from patients with BRAF
wt 
PTCs. Only the 3 
samples from BRAF
V600E
 PTC group were mutated using 454 NGS, in fact no 
mutations were found in PBs from the BRAF
wt 
PTC group. The PBs from 
BRAF
V600E
 PTC group harbored the following BRAF substitutions: V600E (all 3 
cases), T599I (one case), K601R (one case) and V600A (one case) (Table 4.19). 
Functional studies showed that BRAF
T599I
 
mutation leads to BRAF kinase with 
intermediate activity: lower kinase activity 
compared with BRAF
V600E 
but higher than 
BRAF
wt
 (Table 4.19) [130]. To the best of our 
knowledge, no information about BRAF
K601R
 
kinase activity can be found in literature. 
Figure 4.18. Psammoma body in case No.6 (H&E X 600). 
 
Protein 
change 
PB 
Case No. 3 
PB 
Case No. 6 
PB 
Case No. 8 
T599I X 
  
V600E X X X 
K601R 
 
X 
 
V600A X 
  
 
Table 4.19. Exon 15 BRAF mutations in PBs from the group with BRAFV600E PTCs. Possibly and 
probably damaging mutations according to PolyPhen-2 score are shown in orange and benign mutation in 
blue. PB, psammoma body. 
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4.2.4 “Unusual” exon 15 BRAF mutations in histologically benign 
thyroid lesions of the BRAF
V600E
 mutated PTC group 
Mutations previously described in PTC 
Five “unusual” exon 15 BRAF mutations (G593D, A598V, T599I, V600K and 
V600M), previously reported in PTC and scored as possibly or probably 
damaging (PD) by PolyPhen-2 tool, were observed in 4 codons in 8 histologically 
benign thyroid samples of cases with BRAFV600E PTC (Table 4.20). Previous 
functional studies in vitro revealed that BRAF
A598V
 leads to strong up- regulation 
of BRAF kinase activity whereas BRAF
V600K
 implies augmented in vitro kinase 
activity although at a much lower level compared with BRAF
V600E
 [130, 158].  
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Protein 
change 
Histologic 
variant of 
related 
PTC 
Type of 
sample 
Median 
percentage 
of mutated 
allele 
(reads) 
In-silico prediction of 
effect on protein 
function 
(PolyPhen-2) 
References Possible kinase activity 
Score Prediction 
G593D 
PTC TC 
Case No. 
12 
Atypical 
focus 
17% 
(3180) 
1 PD 
COSMIC: 
- thyroid hyperplasia  
- large intestine carcinoma 
Cameselle-Teijeiro J. et al., 
2009: thyroid HYP 
Tie J. et al., 2011: large 
intestine carcinoma 
- 
PTC TC 
Case No. 
13 
Atypical 
focus 
1.8% 
(683) 
A598V 
PTC TC 
Case No. 
13 
Normal 
7% 
(2116) 
0.935 PD 
COSMIC: 
- FV PTC  
- melanoma  
- glioma  
Santarpia L. et al., 2009: FV 
PTC 
Up-regulation 
comparable to BRAFV600E 
(Santarpia L. et al., 2009) 
T599I 
PTC FV 
Case No. 3 
PB 
2.3% 
(750) 
0.652 PD 
COSMIC: 
- large intestine 
carcinoma  
- melanoma  
- benign melanocytic 
nevus  
De Falco V. et al., 2008; 
Chiosea S. et al., 2009: 
complex mutation in PTC 
Jingrong L. et al., 2009: 
melanoma 
Intermediate kinase 
activity: 
much lower kinase 
activity 
compared with 
BRAFV600E 
(Wan P.T. et al., 2004 ) 
PTC Cl 
Case No. 9 
Normal  3% (923) 
PTC TC 
Case No. 
13 
Atypical 
focus 
5% 
(2240) 
V600K 
PTC Cl 
Case No. 4 
Oncocytic 
FA 
5.8% 
(1554) 
1 PD 
COSMIC: 
- melanoma  
- benign melanocytic 
nevus  
- others 
Brzezianska E. et al, 2007: 
PTC 
Lin J. et al., 2011: melanoma 
Intermediate kinase 
activity: 
much lower kinase 
activity 
compared with 
BRAFV600E 
(Wan P.T. et al., 2004 ) 
V600M 
PTC Cl 
Case No. 7 
Atypical 
focus 
3.9% 
(889) 
0.904 PD 
COSMIC: 
- prostatic carcinoma  
- melanoma  
- others  
Brzezianska E. et al., 2007: 
PTC 
Cho N.Y. et al., 2006: 
prostatic carcinoma 
Lin J. et al., 2011: melanoma 
- 
Table 4.20. “Unusual” exon 15 BRAF mutations previously described in PTC and scored as PD in 
histologically benign thyroid from the group with BRAFV600E PTCs. PTC, papillary thyroid carcinoma; 
PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular variant; FA, follicular adenoma; PB, 
psammoma body; PD, possibly or probably damaging mutation. 
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Mutations reported in other tumors 
Four “unusual” exon 15 BRAF mutations (V600A, S605N, S607P and Q609R), 
previously reported in other tumors (prostatic carcinoma, benign melanocytic 
nevus, melanoma and large intestine carcinoma) and scored as benign (B) by 
PolyPhen-2 tool, were observed in 5 histologically benign thyroid lesions of cases 
with BRAF
V600E 
PTC (Table 4.21). PolyPhen-2 score suggests that these amino 
acid changes are tolerated by the protein, however, to the best of our knowledge, 
no further functional studies have been performed. 
Protein change 
Histologic 
variant of 
related 
PTC 
Type of sample 
Median 
percentage of 
mutated allele 
(reads) 
In-silico prediction of 
effect on protein 
function 
(PolyPhen-2) References 
Possible kinase 
activity 
Score Prediction 
V600A 
PTC FV 
Case No. 3 
PB 
2.4% 
(1148) 
0.207 B 
COSMIC:  
- prostatic carcinoma  
- benign melanocytic 
nevus  
 
Cho N.Y. et al., 2006: 
prostatic carcinoma 
Lin J. et al., 2009: 
melanocytic nevi 
- 
PTC TC 
Case No. 
12 
HYP 1% (1534) 
S605N 
PTC TC 
Case No. 
12 
HYP 
1.4% 
(1534) 
0.009 B 
COSMIC:  
melanoma  
 
Deichmann M. et al.: 
melanoma 
- 
S607P 
PTC Cl 
Case No. 4 
Oncocytic 
FA 
 
HYP 
11.7% 
(1876) 
 
30% 
(1119) 
0.186 B 
COSMIC:  
melanoma   
- 
Q609R 
PTC Cl 
Case No. 4 
Normal 
5.5% 
(1623) 
0.017 B 
COSMIC: 
- large intestine 
carcinoma  
-  melanoma  
- 
Table 4.21. “Unusual” exon 15 BRAF mutations previously described in other tumors and scored as B 
in histologically benign thyroid from the group with BRAFV600E PTCs. PTC, papillary thyroid carcinoma; 
PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular variant; HYP, hyperplasia; FA, 
follicular adenoma; PB, psammoma body; B, benign mutation. 
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Ten “unusual” exon 15 BRAF missense mutations (T589I, D594N, G596S, 
L597P, A598T, K601R, R603Q, G606E and S607F) and one nonsense mutation 
(R603*), previously known in other tumors (large intestine carcinoma, melanoma, 
benign melanocytic nevus, lung carcinoma and endometrial carcinoma) and 
scored as possibly or probably damaging (PD) by PolyPhen-2 tool, were observed 
in 9 histologically benign thyroid specimens of cases with BRAFV600E PTC (Table 
4.22).  
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Protein 
change 
Histologic 
variant of 
related PTC 
Type of 
sample 
Median 
percentage of 
mutated allele 
(reads) 
In-silico prediction of 
effect on protein 
function (PolyPhen-2) References 
Possible kinase 
activity 
Score Prediction 
T589I 
PTC Cl 
Case No. 6 
HYP 1.2% (1444) 0.886 PD 
COSMIC:  
large intestine carcinoma  
Konishi K. et al., 2006: colorectal 
adenoma 
Up-regulated 
(Konishi K. et al., 
2006) 
D594N 
PTC Cl 
Case No. 4 
HYP 3% (507) 1 PD 
COSMIC:  
- melanoma  
- benign melanocytic nevus  
- lung carcinoma  
Dahlman K.B. et al.,2012: melanoma  
Inactive 
(Heidorn S.J. et al., 
2010) 
G596S 
PTC Cl 
Case No. 4 
Normal 5.8% (328) 1 PD 
COSMIC:  
 melanoma  
Jovanovic B. et al., 2008: melanoma 
- 
L597P 
sclerosing 
PTC 
Case No. 2 
Normal 3.7% (1234) 0.784 PD 
COSMIC:  
large intestine carcinoma - 
A598T 
PTC TC 
Case No. 12 
HYP 13.8% (4345) 0.871 PD 
COSMIC:  
melanoma  
Deichmann M. et al.,2006: melanoma  
- 
K601R 
PTC Cl 
Case No. 6 
PB 1.5% (691) 
0.494 PD 
COSMIC:  
melanoma  
Lin J. et al., 2011: melanoma  
- 
PTC TC 
Case No. 12 
Atypical 
focus 
7.5% (1122) 
R603Q 
PTC Cl 
Case No. 4 
HYP 1.7% (1305) 
0.786 PD 
Tschandl P. et al., 2013: benign 
melanocytic nevus  - 
PTC TC 
Case No. 12 
HYP 2.4% (1771) 
R603* 
PTC TC 
Case No. 12 
HYP 2.1% (2572) - PD 
COSMIC:  
-  endometrial carcinoma  
-  melanoma  
Feng Y.Z. et al., 2005: endometrial 
carcinoma 
- 
G606E 
PTC Cl 
Case No. 6 
Normal 2.3% (1564) 0.493 PD 
COSMIC:  
 melanoma 
Deichmann M. et al., 2006: melanoma 
- 
S607F 
PTC FV 
Case No. 8 
Normal 3.5% (963) 0.998 PD 
COSMIC: 
lung carcinoma  
Tschandl P. et al., 2013: benign 
melanocytic nevus  
- 
Table 4.22. “Unusual” exon 15 BRAF mutations previously known in other tumors and scored as PD in 
histologically benign thyroid from the group with BRAFV600E PTCs. PTC, papillary thyroid carcinoma; 
PTC Cl, PTC-classic; PTC TC, PTC-tall cell; PTC FV, PTC-follicular variant; HYP, hyperplasia; PB, 
psammoma body; PD, possibly or probably damaging mutation;*, stop codon. 
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Three mutations other than BRAF
V600E
 involved the Val600 residue: two 
mutations, BRAF
V600K 
and BRAF
V600M
, were scored as probably damaging (PD) by 
PolyPhen-2 tool, while BRAF
V600A
 was scored as benign. Previous studies showed 
that BRAF
V600K
, a mutation that causes a substitution of valine for a positively 
charged lysine (in contrast to the BRAF
V600E
 negative charge substitution), is an 
activating mutation [130]. The result of substitutions of uncharged nonpolar 
amino acid (methionine and alanine) for the uncharged nonpolar amino acid 
(valine) on BRAF kinase activity has not been tested through functional studies.  
In Table 4.23 are summarized all exon 15 BRAF
 
mutations scored as possibly or 
probably damaging (PD) or benign (B) found in histologically benign samples 
from the group with BRAF
V600E
 PTCs (A) and with BRAF
wt
 PTCs (B).  
 
Table 4.23. Exon 15 BRAF mutations scored PD or B in histologically benign thyroid from the group 
with BRAFV600E PTCs (A) and with BRAFwt PTCs (B). PTC, papillary thyroid carcinoma; N, normal; A, 
atypical focus; PB, psammoma body; HYP, hyperplasia; Onc FA, oncocytic follicular adenoma; FA, 
follicular adenoma; *, stop codon; PD, possibly or probably damaging mutation; B, benign mutation. 
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CHAPTER 5 
DISCUSSION 
 
5.1 Aim 1 - Clonality of BRAF
V600E
 mutation in PTC  
The possibility to explore genetic heterogeneity and to include this concept in 
personalized medicine has been limited by the methodology employed, especially 
standard Sanger sequencing, the principal method used in laboratories for many 
years. Indeed, Sanger sequencing has low analytical sensitivity and does not allow 
semi-quantitative information on the proportion of mutated alleles [242]. 
However, the present technological developments, especially new deep 
sequencing methods, allow for understanding the extent of genetic heterogeneity 
in cancers. 
Genetic and phenotypic variation can be intertumoral, when heterogeneity is 
identified in tumors affecting different tissue and cell types, in different metastatic 
tumors from a single patient or in individuals with the same tumor type. 
Moreover, it can be also intratumoral, when observed within a given tumor [253]. 
Subclonal populations of mutated cells have been found in metastatic melanoma, 
esophageal adenocarcinoma, breast carcinoma, lung cancer, and colorectal 
carcinomas [258-265]. The issue of tumoral heterogeneity in thyroid tumors is 
still debated [248, 266, 271, 282]. 
BRAF
V600E
 mutation is the most frequent genetic alteration in thyroid cancer and 
shows a high oncogenic potential in thyroid cancer murine models: these findings 
have supported the conviction that BRAF
V600E
 is the original transforming event 
for all BRAF mutated PTCs. However, two recent studies performed using 
pyrosequencing, a method that is both sensitive and semi-quantitative, showed 
that BRAF
V600E
 mutation is a rare occurrence in papillary thyroid cancer and is 
more frequently a subclonal event suggesting that usually it is not an early hit 
during PTC development [248, 266].  
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However, so far an important issue, the effect of non-neoplastic allele 
“contamination” (due to the presence of stromal, endothelial and inflammatory 
cells), has not been taken into consideration during the assessment of BRAF
V600E
 
heterogeneity. 
In this thesis, the BRAF
V600E
 allelic frequency in PTCs was evaluated by 
employing two different highly sensitive and semi-quantitative techniques, a 
mutation specific real-time PCR (ASLNAqPCR) and parallel next generation 
BRAF sequencing (454 NGS) targeted to exon 15 in order to validate the data. 
These techniques had both been previously used to quantify mutated allele 
percentages in tumor samples [245, 249].  
To reduce the bias due to the presence of non-neoplastic cells within PTCs, two 
pathologists estimated the amount of neoplastic cells in each tumor sample and 
the percentage of mutated cells obtained by ASLNAqPCR or 454 NGS was 
normalized according to this proportion. Indeed, results highlight a notable change 
of data when the proportion of neoplastic cells within the samples was taken into 
consideration. 
Three groups of tumors were identified: a first group (approximately 40-45% of 
the cases) had a percentage of mutated neoplastic cells greater than 80%; a second 
small group of tumors (approximately 10% of the cases) showed a number of 
BRAF mutated neoplastic cells below 30%; a third group (approximately 45-50% 
of the cases) had a distribution of BRAF
V600E 
between 30 and 80%.  
In the first group of tumors, harboring a percentage of mutated neoplastic cells 
greater than 80%, BRAF
V600E
 occurred very early during tumorigenesis, probably 
representing the founding genetic alteration, and then propagated to all tumor cells 
reaching a clonal distribution.  
In the second small group of tumors, carrying a percentage of BRAF mutated 
neoplastic cells below 30%, BRAF
V600E
 is likely to represent a late adaptive 
mutation during tumor progression. Noteworthy is that these PTCs would have 
been negative for BRAF mutation after Sanger sequencing. 
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In the third group, characterized by a heterogeneous distribution of BRAF
V600E
, 
the majority of the PTCs showed more than 40% of the neoplastic cells carrying 
BRAF
V600E
, therefore, even if not the founding event, the BRAF
V600E
 mutation 
happened early during tumor development. However, the mutation had a 
subclonal origin since it was present within many but not all tumor cells. 
Moreover, the same distribution of the BRAF
V600E
 mutation and the same three 
groups of tumors were also found among the papillary microcarcinomas. To the 
best of our knowledge, this is the first study that has evaluated the distribution of 
BRAF
V600E
 mutation in mPTCs. Since at least some mPTCs are papillary 
carcinomas diagnosed at a very early stage, it’s possible to assume that cells 
harboring the mutation and wild type cells expand at a similar rate, so that the 
proportion between mutated and non-mutated cells is maintained during tumor 
growth. This hypothesis is also consistent with a model in which the BRAF 
mutation can sometimes be acquired in already established tumors but early 
during tumorigenesis. 
The highly sensitive semi-quantitative techniques used in this study, 
ASLNAqPCR and 454 NGS, and also pyrosequencing used in previous studies by 
Guerra et al. and Gandolfi et al., revealed the existence of a subset of PTC 
harboring a subclonal distribution of the BRAF
V600E
 mutation. 
The mean number of mutated neoplastic cells within the tumor was about 67% 
using ASLNAqPCR and about 72% by 454 NGS, corresponding to approximately 
35% of mutated alleles (considering the BRAF
V600E
 mutation heterozygous). 
These numbers are higher than those reported by Guerra et al. and Gandolfi et al. 
and are in general agreement with the recent NGS data of Nikiforova et al.[248, 
266, 271]. 
This discrepancy with the data reported by Guerra et al. and Gandolfi et al. is 
most likely due to the normalization on the estimated proportion of neoplastic 
cells within the tumor that we performed. Indeed, the proportion of mutated 
neoplastic cells in non normalized data is similar to that previously reported in 
PTCs based on pyrosequencing analysis of the BRAF
V600E
 mutation. 
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No statistical association between the percentage of BRAF
V600E
 mutated neoplastic 
cells and tumor size, stage, age at presentation, or presence of lymph node 
metastasis could be demonstrated. 
In summary, this project demonstrated that in many PTCs the BRAF
V600E
 has a 
homogeneous distribution in virtually all neoplastic cells and probably represents 
the founding genetic alteration. However, in a large percentage of PTCs, 
BRAF
V600E
 has a heterogeneous distribution being present in many but not all 
neoplastic cells. Therefore, even if BRAF
V600E
 is not always the initial event in the 
neoplastic thyrocyte transformation, it is acquired early during PTC 
tumorigenesis.  
The presence of genetically distinct tumor subclones with different BRAF status 
might influence the efficacy of and resistance to targeted pharmacotherapy and be 
useful to guide patient management. Indeed, in a situation of intratumor 
heterogeneity, cancer treatment may lead to the eradication of sensitive clones and 
emergence of often pre-existing treatment-resistant subclones.  
Therefore, understanding the extent of genetic heterogeneity in cancer will 
probably improve the design of individualized treatment through the use of 
combinatorial therapeutic agents in order to reduce the emergence of resistant 
clones. 
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5.2 Aim 2 - Screening of BRAF mutations in exon 15 in 
histologically benign thyroid tissue 
The present study revealed the occurrence of a total of 21 BRAF
 
mutations at 14 
sites in 21 histologically benign FFPE thyroid specimens out of 75 samples (28%) 
from the group with BRAF
V600E
 mutated PTCs and the presence of 3 BRAF
 
mutations in 2 out of 23 samples (8.7%) from the group with BRAF
wt
 PTCs using 
the 454 Next-Generation Sequencing (NGS) semi-quantitative technique. 
According to the World Health Organization Classification of Tumors of 
Endocrine Organs, published in 2004, there is no known precursor lesion of 
papillary thyroid carcinoma [4].  
High sensitivity molecular analysis may be helpful in the assessment of early 
events in thyroid cancer development. In this study, high sensitivity semi-
quantitative mutational analysis identified a BRAF
K601E
 mutation in one FA: the 
same mutation had been described in previous studies by conventional sequencing 
only in two follicular adenomas, one from a study in post-Chernobyl tumors [64, 
141, 144]. This finding strengthens the hypothesis of an association between 
BRAF
K601E
 mutation and the follicular growth pattern also in benign thyroid 
tumors and suggests that high sensitivity mutational analysis will be helpful in the 
assessment of the frequency of this mutation also in benign thyroid tumors. 
Moreover, high sensitivity mutational analysis identified the presence of 
BRAF
V600E 
mutation in psammoma bodies (PBs) here analyzed. PBs are rounded 
and concentrically lamellated calcifications observed in PTC and rarely in 
histologically benign lesions and considered the remnants of neoplastic papillae. 
Indeed, residual neoplastic cells are sometimes observed intimately associated 
with PBs in PTC during histological observation [86]. BRAF
V600E 
 mutation was 
observed in all 3 psammoma bodies not associated with histologically identifiable 
tumor cells in the group of BRAF
V600E
 PTCs: this molecular analysis confirms the 
hypothesis long held by pathologists that PBs represent, also in benign lesions, the 
remnants of neoplastic papillae which once existed in these lesions. 
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In this study, BRAF
V600E 
mutation was found also in “atypical foci”, areas of 
thyroid parenchyma with abnormal cells, but with morphologic alterations below 
the threshold that the pathologists consider to diagnose malignancy, i.e. papillary 
carcinoma. Two groups of cases were studied: one consisted of 20 cases with 
BRAF
V600E
 mutated PTC, the other of 9 BRAF
wt
 PTCs. Since BRAF
V600E
 is a 
specific marker of papillary thyroid carcinoma, these lesions probably represent 
the precursors of BRAF
V600E
 mutated PTCs. In the first group, the presence of the 
same BRAF
V600E 
mutation in both atypical focus and PTC and the occurrence in 
the same thyroid lobe, suggest a histogenetic relationship between the 
histologically benign lesion and the PTC. In the second group, the presence of 
BRAF
V600E 
mutation in the atypical focus and its absence in the tumor suggests a 
possible genetic heterogeneity of the tumor and the atypical focus. 
In this case, also a BRAF
E586K 
was identified in the same focus of “atypical” cells. 
BRAF
E586K 
mutation, that may affect protein function according to physical and 
comparative considerations of PolyPhen-2 tool and with elevated in vitro kinase 
activity, may affect a different subclone in the atypical focus. Indeed, the different 
percentages of BRAF
E586K 
and BRAF
V600E
 mutated alleles lead to hypothesize that 
the two mutations occur into two different cellular clones.  
454 Sequencing system allows not only targeted re-sequencing for each amplicon 
hundreds to thousands of times but also an unambiguous haplotyping. 
Brzeziańska et al., performed mutational screening of exon 15 of BRAF gene by 
direct sequencing in PTC and observed G1798A and T1799A mutations in the 
same PTC. They suggested that these substitutions were most likely to occur on 
the same chromosome resulting in a BRAF
V600K
 mutation in one allele. BRAF
V600K
 
mutation is the result of a 2-bp change (GT1798-1799AA), whereas V600M is the 
result of a single nucleotide substitution in the first nucleotide position (G1798A) 
in codon 600 of BRAF gene: these mutations had not been previously described in 
thyroid tumors. [150]. The study by Brzeziańska et al., highlights the limits of 
Sanger sequencing in the assessment of genetic heterogeneity. These mutations 
were unambiguously observed also in this study. Indeed, three mutations other 
than BRAF
V600E
 involved Val600 residue: BRAF
V600K 
and BRAF
V600M
 were scored 
as probably damaging by PolyPhen-2 tool, whereas BRAF
V600A
 was scored as 
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benign. BRAF
V600K 
and BRAF
V600M
 were found in an oncocytic follicular adenoma 
and in an atypical focus respectively.  
Previous studies showed that BRAF
V600K
, which causes a substitution of valine for 
a positively charged lysine (in contrast to the BRAF
V600E
 negative charge 
substitution), is an activating mutation. However, this variant was shown to have 
much lower kinase activity compared with BRAF
V600E
 [130].  
The result of substitutions of uncharged nonpolar amino acid such as methionine 
and alanine for the uncharged nonpolar amino acid valine on BRAF kinase 
activity has not been tested through functional studies [118, 152, 153]. 
No mutations (other than BRAF
V600E
) were identified in nearly every BRAF
V600E
 
PTC sample. In only one case the same mutation, BRAF
T599I
, was found at low 
frequency both in BRAF
V600E
 PTC and normal tissue from the same thyroid lobe. 
In BRAF threonine 599 is the major activation segment phosphorylation site and 
its replacement with isoleucine activates in vitro BRAF similarly to what happens 
during threonine 599 phosphorylation. However, Wan et al. showed that also the 
protein product of this variant has much lower kinase activity in vitro compared 
with BRAF
V600E
 [130]. The presence of the same BRAF
T599I
 mutation at low 
frequency in both normal tissue and classic PTC indicates a weak action of this 
activating variant on thyrocytes. 
Therefore, cell clones harboring BRAF
T599I
 and BRAF
V600K
 variants may have 
weaker growth advantage than those carrying the BRAF
V600E
 mutation and may be 
undergo negative selection in the tumor or remain a minor subpopulation. 
Similarly, marked polyclonality of BRAF mutations was observed by Lin et al. in 
acquired melanocytic nevi: in their study, cells with rare BRAF mutations, such as 
BRAF
T599I
, BRAF
V600K 
and BRAF
V600A
, all of which previously described in 
melanoma lesions, were found in nevi harboring also BRAF
V600E
 mutation and 
cells with wild-type BRAF [153, 154]. However, they found frequent 
heterogeneity of BRAF mutations also in primary melanomas that were wild type 
by direct sequencing. They found melanomas containing tumor cells with wild-
type BRAF, BRAF
V600E
 and other activating BRAF mutations in minor 
subpopulations that did not outgrow BRAF
wt 
cells [152]. 
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These findings are consistent with the classical multi-step model of thyroid 
carcinogenesis. Risk factors, including exposure to radiation, induce genetic 
instability, resulting in early genetic alterations that involve the effectors of 
mitogen activated protein kinase (MAPK) signaling pathway such as BRAF. In 
this context, the possibly damaging BRAF
 
mutations other than BRAF
V600E
 in exon 
15 found in histologically benign thyroid tissue of cases with BRAFwt and 
BRAF
V600E
 PTC by high sensitive semi-quantitative analysis seem to represent 
early weak neoplastic transformation events that result in “abortive” attempts at 
thyroid cancer development. Only in the case of BRAF
V600E 
mutation the drive to 
neoplastic transformation seems to be strong enough to result in a full blown PTC. 
Further functional characterization of possibly damaging BRAF mutations would 
be useful in order to understand whether the cells harboring these variant 
mutations show any significant growth advantage. 
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